

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, 48/00, C12P 19/34, C12Q 1/68, G01N 33/53, 33/574, 33/546, 33/567		A1	(11) International Publication Number: WO 00/23111 (43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/US99/24331 (22) International Filing Date: 19 October 1999 (19.10.99)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/104,737 19 October 1998 (19.10.98) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment #218, 350 Elan Village Lane, San Jose, CA 95134 (US).			
(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).			

(54) Title: METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING PROSTATE CANCER

(57) Abstract

The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING PROSTATE CANCER**

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating cancers, particularly
prostate cancer.

BACKGROUND OF THE INVENTION

Cancer of the prostate is the most prevalent malignancy
10 in adult males, excluding skin cancer, and is an increasingly
prevalent health problem in the United States. In 1996, it
was estimated that 41,400 deaths would result from this
disease in the United States alone, indicating that prostate
cancer is second only to lung cancer as the most common cause
15 of death in the same population. If diagnosed and treated
early, when the cancer is still confined to the prostate, the
chances of cure is significantly higher.

Treatment decisions for an individual are linked to the
stage of prostate cancer present in that individual. A common
20 classification of the spread of prostate cancer was developed
by the American Urological Association (AUA). The AUA system
divides prostate tumors into four stages, A to D. Stage A,
microscopic cancer within prostate, is further subdivided into
stages A1 and A2. Sub-stage A1 is a well-differentiated
25 cancer confined to one site within the prostate. Treatment
is generally observation, radical prostatectomy, or radiation.
Sub-stage A2 is a moderately to poorly differentiated cancer
at multiple sites within the prostate. Treatment is radical
prostatectomy or radiation. Stage B, palpable lump within the
30 prostate, is also further subdivided into sub-stages B1 and
B2. In sub-stage B1, the cancer forms a small nodule in one

- 2 -

lobe of the prostate. In sub-stage B2, the cancer forms large or multiple nodules, or occurs in both lobes of the prostate. Treatment for sub-stages B1 and B2 is either radical prostatectomy or radiation. Stage C is a large cancer mass 5 involving most or all of the prostate and is also further subdivided into two sub-stages. In sub-stage C1, the cancer forms a continuous mass that may have extended beyond the prostate. In sub-stage C2, the cancer forms a continuous mass that invades the surrounding tissue. Treatment for both these 10 sub-stages is radiation with or without drugs to address the cancer. The fourth stage, Stage D is metastatic cancer and is also subdivided into two sub-stages. In sub-stage D1, the cancer appears in the lymph nodes of the pelvis. In sub-stage D2, the cancer involves tissues beyond lymph nodes. Treatment 15 for both of these sub-stages is systemic drugs to address the cancer as well as pain.

However, current prostate cancer staging methods are limited. As many as 50% of prostate cancers initially staged as A2, B, or C are actually stage D, metastatic. Discovery 20 of metastasis is significant because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers. The five year survival rates for patients with localized and metastatic prostate cancers are 93% and 29%, respectively.

25 Accordingly, there is a great need for more sensitive and accurate methods for the staging of a cancer in a human to determine whether or not such cancer has metastasized and for monitoring the progress of a cancer in a human which has not metastasized for the onset of metastasis.

30 It has now been found that a number of proteins in the public domain are useful as diagnostic markers for prostate cancer. These diagnostic markers are referred to herein as cancer specific genes or CSGs and include, but are not limited to: Pro109 which is a human zinc- α 2-glycoprotein (Freje et 35 al. Genomics 1993 18(3):575-587); Pro112 which is a human

- 3 -

cysteine-rich protein with a zinc-finger motif (Liebhaber et al. Nucleic Acid Research 1990 18(13):3871-3879; WO9514772 and WO9845436); Pro111 which is a prostate-specific transglutaminase (Dubbink et al. Genomics 1998 51(3):434-444); 5 Pro115 which is a novel serine protease with transmembrane, LDLR, and SRCR domains and maps to 21q22.3 (Paoloni-Giacobino et al. Genomics 1997 44(3):309-320; WO9837418 and WO987093); Pro110 which is a human breast carcinoma fatty acid synthase (U.S. Patent 5,665,874 and WO9403599); Pro113 which is a 10 homeobox gene, HOXB13 (Steinicki et al. J. Invest. Dermatol. 1998 111:57-63); Pro114 which is a human tetraspan NET-1 (WO9839446); and Pro118 which is a human JM27 protein (WO9845435). ESTs for these CSGs are set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13 and 15 while the full length contigs for 15 these CSGs are set forth in SEQ ID NO:2, 4, 6, 8, 10, 12, 14 and 16, respectively. Additional CSGs for use in the present invention are depicted herein in SEQ ID NO: 17, 18, 19 and 20.

In the present invention, methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, 20 imaging and treating prostate cancer via the cancer specific genes referred to herein as CSGs. For purposes of the present invention, CSG refers, among other things, to native protein expressed by the gene comprising a polynucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 25 16, 17, 18, 19 or 20. By "CSG" it is also meant herein polynucleotides which, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1-20, but which still encode the same protein. In the alternative, what is meant by CSG as used herein, means the 30 native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 35 20, or levels of a polynucleotide which is capable of

- 4 -

hybridizing under stringent conditions to the antisense sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20:

Other objects, features, advantages and aspects of the 5 present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various 10 changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

15 Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of prostate cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid 20 type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with prostate cancer.

Further provided is a method of diagnosing metastatic prostate cancer in a patient having prostate cancer which is 25 not known to have metastasized by identifying a human patient suspected of having prostate cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the 30 same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient versus the normal human control is associated with prostate cancer which has metastasized.

- 5 -

Also provided by the invention is a method of staging prostate cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient 5 for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer 10 which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring prostate cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient 15 having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of 20 a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided is a method of monitoring the change in stage of prostate cancer in a human having such cancer by 25 looking at levels of CSG in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of 30 CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is 35 regressing or in remission.

- 6 -

Further provided are methods of designing new therapeutic agents targeted to a CSG for use in imaging and treating prostate cancer. For example, in one embodiment, therapeutic agents such as antibodies targeted against CSG or 5 fragments of such antibodies can be used to detect or image localization of CSG in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal, monoclonal, or omniclonal or prepared by molecular biology techniques. The term "antibody", as used herein and 10 throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, 15 but not limited to, radioisotopes and paramagnetic metals. Therapeutic agents such as antibodies or fragments thereof can also be used in the treatment of diseases characterized by expression of CSG. In these applications, the antibody can be used without or with derivatization to a cytotoxic agent 20 such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the 25 specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and 30 from reading the other parts of the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers

- 7 -

by comparing levels of CSG in a human patient with those of CSG in a normal human control. For purposes of the present invention, what is meant by CSG levels is, among other things, native protein expressed by the gene comprising a 5 polynucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. By "CSG" it is also meant herein polynucleotides which, due to degeneracy in genetic coding, comprise variations in nucleotide sequence as compared to SEQ ID NO: 1-20, but which still encode the 10 same protein. The native protein being detected, may be whole, a breakdown product, a complex of molecules or chemically modified. In the alternative, what is meant by CSG as used herein, means the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:1, 2, 3, 15 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20, or levels of a polynucleotide which is capable of hybridizing under stringent conditions to the 20 antisense sequence of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. Such levels are preferably determined in at least one of, cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in 25 accordance with the invention for diagnosing overexpression of CSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of prostate cancer.

All the methods of the present invention may optionally 30 include determining the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

- 8 -

Diagnostic Assays

The present invention provides methods for diagnosing the presence of prostate cancer by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels 5 of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of CSG in the patient versus the normal human control is associated with the presence of prostate cancer.

Without limiting the instant invention, typically, for 10 a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, 15 tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic prostate cancer in a patient having prostate cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a 20 human cancer patient suspected of having prostate cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.

In the present invention, determining the presence of CSG 25 levels in cells, tissues or bodily fluid, is particularly useful for discriminating between prostate cancer which has not metastasized and prostate cancer which has metastasized. Existing techniques have difficulty discriminating between prostate cancer which has metastasized and prostate cancer 30 which has not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, 35 tissue or bodily fluid type of a normal human control. That

- 9 -

is, if the cancer marker being observed is just CSG in serum, this level is preferably compared with the level of CSG in serum of a normal human control. An increase in the CSG in the patient versus the normal human control is associated with 5 prostate cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid 10 levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal patient.

Normal human control as used herein includes a human 15 patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably also include samples from a human patient that is determined by reliable methods to have prostate cancer which has not metastasized.

20 ***Staging***

The invention also provides a method of staging prostate cancer in a human patient. The method comprises identifying a human patient having such cancer and analyzing cells, tissues or bodily fluid from such human patient for CSG. The 25 CSG levels determined in the patient are then compared with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and 30 a decrease in the levels of CSG (but still increased over true normal levels) is associated with a cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring prostate 35 cancer in a human patient having such cancer for the onset of

- 10 -

metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing cells, tissues or bodily fluid from such human patient for CSG; and comparing the CSG levels 5 determined in the human patient with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which has metastasized. In this method, normal 10 human control samples may also include prior patient samples.

Further provided by this invention is a method of monitoring the change in stage of prostate cancer in a human patient having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing 15 cells, tissues or bodily fluid from such human patient for CSG; and comparing the CSG levels determined in the human patient with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CSG levels in the human patient versus 20 the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission. In this method, normal human control samples may also include prior patient samples.

25 Monitoring a patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

Assay Techniques

30 Assay techniques that can be used to determine levels of gene expression (including protein levels), such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse 35 transcriptase PCR (RT-PCR) assays, immunohistochemistry

- 11 -

assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass 5 spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific 10 to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme 15 or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific 20 protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to a detectable 25 reagent such as horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added 30 to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard 35 curve.

- 12 -

A competition assay can also be employed wherein antibodies specific to CSG are attached to a solid support and labeled CSG and a sample derived from the host are passed over the solid support. The amount of label detected which is 5 attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods can also be used to detect CSG mRNA as a marker for prostate cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain 10 reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population 15 in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the 20 presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on 25 a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or 30 plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte 35 can be detected and quantitated by several means including but

- 13 -

not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the 5 analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a 10 technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric 15 current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since 20 no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or 25 subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a 30 patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of 35 blood.

- 14 -

In Vivo Targeting of CSGs

Identification of these CSGs is also useful in the rational design of new therapeutics for imaging and treating cancers, and in particular prostate cancer. For example, in 5 one embodiment, antibodies which specifically bind to CSG can be raised and used *in vivo* in patients suspected of suffering from prostate cancer. Antibodies which specifically bind a CSG can be injected into a patient suspected of having prostate cancer for diagnostic and/or therapeutic purposes.

10 The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscintographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 15 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described 20 (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSG can be used in a similar manner. Labeled antibodies which specifically bind CSG can be injected into patients suspected of having prostate cancer for the purpose of diagnosing or staging of the disease 25 status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting 30 labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an organ or

- 15 -

tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with prostate cancer, injection of an antibody which specifically binds CSG can also have a 5 therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody can be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and 10 Baldwin, Cancer Research 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor 15 while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CSG.

20 Antibodies which can be used in these *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* 25 evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

Small molecules predicted via computer imaging to specifically bind to regions of CSGs can also be designed and synthesized and tested for use in the imaging and treatment 30 of prostate cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to CSGs identified herein. Molecules identified in the library as being capable of binding to CSG are key candidates for further evaluation for 35 use in the treatment of prostate cancer.

- 16 -

EXAMPLES

The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments.

5 These exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

All examples outlined here were carried out using standard techniques, which are well known and routine to those 10 of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory 15 Press, Cold Spring Harbor, N.Y. (1989).

Example 1: Identification of CSGs

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, CA, using the data mining Cancer 20 Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus 25 all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease; selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor 30 libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

- 17 -

Clones depicted in the following Table 1 are CSGs useful in diagnosing, monitoring, staging, imaging and treating prostate cancer.

Table 1: CSGs

	Clone ID	Pro #	SEQ ID NO:
5	3424528H1	Pro109	1, 2
	578349H1	Pro112	3, 4
	1794013H1	Pro111	5, 6
	2189835H1	Pro115	7, 8
10	3277219H1	Pro110	9, 10
	1857415	Pro113	11, 12
	1810463H1	Pro114	13, 14
	zr65G11	Pro118	15, 16
	2626135H1		17
15	zd46d08		18
	1712252H1		19
	784583H1		20

Example 2: Relative Quantitation of Gene Expression

20 Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. 25 During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

30 Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous

- 18 -

control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator).
5 using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene were evaluated for every sample in normal and cancer tissues. Total RNA was extracted from normal tissues, cancer tissues,
10 and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probes specific to each target gene. The results were analyzed using the ABI PRISM 7700
15 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Expression of Clone ID 3424528H1 (Pro109):

For the CSG Pro109, real-time quantitative PCR was
20 performed using the following primers:

Forward Primer:

5' - ATCAGAACAAAGAGGGCTGTGTC - 3' (SEQ ID NO:21)

Reverse Primer:

5' - ATCTCTAAAGCCCCAACCTTC - 3' (SEQ ID NO:22)

25 The absolute numbers depicted in Table 2 are relative levels of expression of the CSG referred to as Pro109 in 12 normal different tissues. All the values are compared to normal stomach (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular
30 tissue from different individuals.

- 19 -

Table 2: Relative Levels of CSG Pro109 Expression in Pooled Samples

5	Tissue	NORMAL
	Colon	0.02
	Endometrium	0.01
	Kidney	0.48
	Liver	14.83
	Ovary	0.08
10	Pancreas	4.38
	Prostate	11.24
	Small Intestine	0.42
	Spleen	0
	Stomach	1
15	Testis	0.62
	Uterus	0.02

The relative levels of expression in Table 2 show that with the exception of liver (14.83), Pro109 mRNA expression is higher (11.24) in prostate compared with all other normal tissues analyzed. Pancreas, with a relative expression level of 4.38, is the only other tissue expressing considerable mRNA for Pro109.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

The absolute numbers depicted in Table 3 are relative levels of expression of Pro109 in 28 pairs of matching samples and 4 unmatched samples. All the values are compared to 30 normal stomach (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

- 20 -

Table 3: Relative Levels of CSG Pro109 Expression in Individual Samples

	Sample ID	Tissue	Cancer	Matching Normal Adjacent
5	Pro34B	Prostate 1	5.98	6.06
10	Pro65XB	Prostate 2	16.68	3.85
15	Pro69XB	Prostate 3	20.46	6.82
20	Pro78XB	Prostate 4	1.39	1.4
25	Pro101XB	Prostate 5	24.8	9.8
	Pro12B	Prostate 6	9.1	0.2
	Pro13XB	Prostate 7	0.5	9.7
	Pro20XB	Prostate 8	13	12.5
	Pro23B	Prostate 9	16.8	3
	Ovr10005O	Ovary 1	0.4	
	Ovr1028	Ovary 2	1.9	
	Ovr18GA	Ovary 3		0.1
	Ovr206I	Ovary 4		0.1
	Mam12X	Mammary Gland 1	13.5	1.4
	Mam47XP	Mammary Gland 2	0.7	0.2
	Lng47XQ	Lung 1	2.36	0.03
	Lng60XL	Lung 2	7.39	0.2
	Lng75XC	Lung 3	0.77	0.27
	StoAC44	Stomach 1	0.05	1.19
	StoAC93	Stomach 2	0.55	0.8
	StoAC99	Stomach 3	0.12	3.04
	ColAS43	Colon 1	16.11	0.07
	ColAS45	Colon 2	0.11	0.06
	ColAS46	Colon 3	4.99	0.4
	Liv15XA	Liver 1	8.43	10.97
	Liv42X	Liver 2	1.57	20.82

- 21 -

Liv94XA	Liver 3	2.98	9.19
Pan77X	Pancreas 1	36	32
Pan82XP	Pancreas 2	0.09	7.09
Pan92X	Pancreas 3	0.7	0
Pan71XL	Pancreas 4	2.48	0.73
Pan10343	Pancreas 5	46	5.5

0 = Negative

5 In the analysis of matching samples, the higher levels of expression were in prostate, showing a high degree of 10 tissue specificity for prostate tissue. Of all the samples different than prostate analyzed, only 4 cancer samples (the cancer sample mammary 1 with 13.5, colon 1 with 16.11, liver 1 with 8.43, and lung 2 with 7.39) showed an expression comparable to the mRNA expression in prostate. These results 15 confirmed some degree of tissue specificity as obtained with the panel of normal pooled samples (Table 2).

Furthermore, the level of mRNA expression was compared 20 in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Pro109 in 6 out 25 of 9 primary prostate cancer tissues compared with their respective normal adjacents. Thus, overexpression in the cancer tissue was observed in 66.66% of the prostate matching samples tested (total of 9 prostate matching samples).

30 Altogether, the degree of tissue specificity, plus the mRNA overexpression in 66.66% of the primary prostate matching samples tested is indicative of Pro109 being a diagnostic marker for prostate cancer.

- 22 -

Expression of Clone ID 578349H1 (Pro112):

For the CSG Pro112, real-time quantitative PCR was performed using the following primers:

Forward Primer

5' - TGCCGAAGAGGTTCACTGC - 3' (SEQ ID NO:23)

Reverse Primer

5' - GCCACAGTGGTACTGTCCAGAT - 3' (SEQ ID NO:24)

The absolute numbers depicted in Table 4 are relative levels of expression of the CSG Pro112 in 12 normal different 10 tissues. All the values are compared to normal thymus (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 4: Relative Levels of CSG Pro112 Expression in Pooled

15 **Samples**

Tissue	NORMAL
Brain	2.9
Heart	0.1
Kidney	0.2
Liver	0.2
Lung	7.7
Mammary	4.2
Muscle	0.1
Prostate	5.5
Small Intestine	1.8
Testis	1
Thymus	1
Uterus	21

The relative levels of expression in Table 4 show that 30 Pro112 mRNA expression is the 3rd most highly expressed gene (after uterus and mammary) in the pool of normal prostate tissue compared to a total of 12 tissues analyzed. The absolute numbers in Table 4 were obtained analyzing pools of samples of a particular tissue from different individuals. 35 These results demonstrate that Pro112 mRNA expression is specific for prostate thus indicating Pro112 to be a diagnostic marker for prostate disease especially cancer.

- 23 -

Expression of Clone ID 1794013H1 (Pro111):

For the CSG Pro111, real-time quantitative PCR was performed using the following primers:

Forward Primer

5' - GCTGCAAGTTCTCCACATTGA - 3' (SEQ ID NO:25)

Reverse Primer

5' - CAGCCGCAGGTGAAACAC - 3' (SEQ ID NO:26)

The absolute numbers depicted in Table 5 are relative levels of expression of the CSG Pro111 in 12 normal different 10 tissues. All the values are compared to normal testis (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

15 **Table 5: Relative Levels of CSG Pro111 Expression in Pooled Samples**

Tissue	NORMAL
Brain	0.04
Heart	0
Kidney	0
Liver	0
Lung	0.05
Mammary	0.14
Muscle	5166.6
Prostate	1483.72
Small Intestine	0.33
Testis	1
Thymus	0.49
Uterus	0.07

20 The relative levels of expression in Table 5 show that Pro111 mRNA expression is extraordinarily high in the pool of normal prostate (1483.72) compared to all the other tissues analyzed with the exception of muscle (5166.6). These results demonstrate that Pro111 mRNA expression shows specificity for prostate and muscle.

25 The absolute numbers in Table 5 were obtained analyzing pools of samples of a particular tissue from different

- 24 -

individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 6.

The absolute numbers depicted in Table 6 are relative levels of expression of Pro111 in 48 pairs of matching and 18 unmatched samples. All the values are compared to normal testis (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 6: Relative Levels of CSG Pro111 Expression in Individual Samples

	Sample ID	Tissue	Cancer	Matching Normal Adjacent
15	Pro101XB	Prostate 1	8.3	21.8
	Pro12B	Prostate 2	2336	133
	Pro13XB	Prostate 3	3.4	23
	Pro20XB	Prostate 4	21.6	121.5
	Pro23B	Prostate 5	19.4	3.7
20	Pro34B	Prostate 6	15	39
	Pro65XB	Prostate 7	8	867
	Pro69XB	Prostate 8	56	94
	Pro78XB	Prostate 9	24	1515
	Pro84XB	Prostate 10	119	15.35
25	Pro90XB	Prostate 11	8.08	112.2
	Pro91XB	Prostate 12	0.88	51.8
	ProC215	Prostate 13	0.3	
	ProC234	Prostate 14	0.35	
	ProC280	Prostate 15	436.5	
30	Pro109XB	Prostate 16	3.43	265
	Pro110	Prostate 17	18.2	8.73

- 25 -

	Pro125XB	Prostate 18	0.34	186
	Pro326	Prostate 19	1392	110
	Pro10R	Prostate 20 (prostatitis)	0.5	
	Pro20R	Prostate 21 (prostatitis)	24.1	
5	Pro258	Prostate 22 (BPH)	4610	
	Pro263C	Prostate 23 (BPH)	0	
	Pro267A	Prostate 24 (BPH)	1.46	
	Pro271A	Prostate 25 (BPH)	0	
	Pro460Z	Prostate 26 (BPH)	1.47	
10	ProC032	Prostate 27 (BPH)	14.4	
	Tst39X	Testis 1	0	0
	Bld32XK	Bladder 1	0.44	0.41
	Bld46XK	Bladder 2	0	0
	Bld66X	Bladder 3	0	0
15	BldTR14	Bladder 4	0	0
	Kid106XD	Kidney 1	0	0
	Kid107XD	Kidney 2	0	0
	Kid109XD	Kidney 3	0	0
	Pan10343	Pancreas 1	0	0
20	Pan71XL	Pancreas 2	0	0
	Pan77X	Pancreas 3	0	0
	Liv15XA	Liver 1	0	0
	Liv42X	Liver 2	0	0
	ClnAS43	Colon 1	0	0
25	ClnAS45	Colon 2	0	0
	ClnAS46	Colon 3	0	0
	ClnAS67	Colon 4	0	0
	ClnAC19	Colon 5	0	0
	ClnAS12	Colon 6	0	0

- 26 -

	SmI21XA	Small Intestine 1	0	0
	SmIH89	Small Intestine 2	0	0
	Lng47XQ	Lung 1	0.7	0
	Lng60XL	Lung 2	0	0
5	Lng75XC	Lung 3	0	0
	Lng90X	Lung 4	0	0
	Mam12X	Mammary Gland 1	0	1.4
	Mam59X	Mammary Gland 2	0.2	0
	MamA06X	Mammary Gland 3	0	0
10	MamS127	Mammary Gland 4	0	0
	Mam162X	Mammary Gland 5	0	0
	Mam42DN	Mammary Gland 6	0	0
	Ovr103X	Ovary 1	0.14	0
	Ovr1005O	Ovary 2	0.2	
15	Ovr1028	Ovary 3	0	
	Ovr1040O	Ovary 4	0.2	
	Ovr18GA	Ovary 5		0
	Ovr206I	Ovary 6		0
	Ovr20GA	Ovary 7		0.2
20	Ovr25GA	Ovary 8		0

0= Negative

In the analysis of matching samples, the higher levels of expression were in prostate showing a high degree of tissue specificity for prostate. These results confirm the tissue specificity results obtained with normal pooled samples (Table 5).

Furthermore, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 6 shows overexpression of Prol11 in 5 out

- 27 -

of 16 primary prostate cancer samples compared with their respective normal adjacent (prostate samples 2, 5, 10, 17, and 19). Similar expression levels were observed in 3 unmatched prostate cancers (prostate samples 13, 14, 15), 2 prostatitis 5 (prostate samples 20, 21), and 6 benign prostatic hyperplasia samples (prostate samples 22 through 27). Thus, there is overexpression in the cancer tissue of 31.25% of the prostate matching samples tested (total of 16 prostate matching samples).

10 Altogether, the high level of tissue specificity, plus the mRNA overexpression in 31.25% of the prostate matching samples tested are indicative of Pro111 being a diagnostic marker for prostate cancer.

Expression of Clone ID 2189835H1 (Pro115):

15 For the CSG Pro115, real-time quantitative PCR was performed using the following primers:

Forward Primer

5' - TGGCTTTGAACTCAGGGTCA - 3' (SEQ ID NO:27)

Reverse Primer

20 5' - CGGATGCACCTCGTAGACAG - 3' (SEQ ID NO:28)

The absolute numbers depicted in Table 7 are relative levels of expression of the CSG Pro115 in 12 normal different tissues. All the values are compared to normal thymus (calibrator). These RNA samples are commercially available 25 pools, originated by pooling samples of a particular tissue from different individuals.

Table 7: Relative Levels of CSG Pro115 Expression in Pooled Samples

Tissue	NORMAL
Brain	0.016
Heart	0.002
Kidney	8.08
Liver	2.20
Lung	112.99

- 28 -

5

Mammary	29.45
Muscle	0.05
Prostate	337.79
Small Intestine	7.54
Testis	1.48
Thymus	1
Uterus	1.4

The relative levels of expression in Table 7 show that Prol15 mRNA expression is higher (337.79) in prostate compared 10 with all the other normal tissues analyzed. Lung, with a relative expression level of 112.99, and mammary (29.446) are the other tissues expressing moderate levels of mRNA for Prol15. These results establish Prol15 mRNA expression to be highly specific for prostate.

15 The absolute numbers in Table 7 were obtained analyzing pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 8.

20 The absolute numbers depicted in Table 8 are relative levels of expression of Prol15 in 17 pairs of matching and 21 unmatched samples. All the values are compared to normal thymus (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the 25 normal adjacent sample for that same tissue from the same individual.

Table 8: Relative Levels of CSG Prol15 Expression in Individual Samples

30

Sample ID	Tissue	Cancer	Matching Normal Adjacent
Pro12B	Prostate 1	1475.9	190.3
ProC234	Prostate 2	169.61	
Pro109XB	Prostate 3		639.53
Pro101XB	Prostate 4	1985.2	2882.9

- 29 -

	Pro13XB	Prostate 5	34.9	13.9
	Pro215	Prostate 6	525.59	
	Pro125XB	Prostate 7		556.05
	Pro23B	Prostate 8	1891.4	1118.6
5	ProC280	Prostate 9	454.3	
	Pro20XB	Prostate 10	1332.6	
	Pro34B	Prostate 11		362.91
	Pro65XB	Prostate 12		135.06
	Pro69XB	Prostate 13		179.67
	Pro10R	Prostate 14 (prostatitis)	143.82	
	Pro20R	Prostate 15 (prostatitis)	397.79	
	Pro258	Prostate 16 (BPH)	216.6	
	Pro263C	Prostate 17 (BPH)	601.25	
	Pro267A	Prostate 18 (BPH)	200.28	
15	Pro271A	Prostate 19 (BPH)	111.43	
	Pro460Z	Prostate 20 (BPH)	53.84	
	ProC032	Prostate 21 (BPH)	56.94	
	Smi21XA	Small Intestine 1	28.8	29.9
	SmiH89	Small Intestine 2	70.8	348.5
20	ClnAC19	Colon 1	22.73	446.47
	ClnAS12	Colon 2	116.97	493.18
	Kid106XD	Kidney 1	86.13	41.14
	Kid107XD	Kidney 2	0.26	35.14
	Lng47XQ	Lung 1	5.13	20.98
25	Lng60XL	Lung 2	13.93	114.78
	Lng75XC	Lung 3	16.47	53.79
	Mam12X	Mammary Gland 1	6.25	10.75
	Mam162X	Mammary Gland 2	1.84	2.54
	Mam42DN	Mammary Gland 3	23.08	35.51

- 30 -

Ovr10050	Ovary 1	0.9	
Ovr1028	Ovary 2	261.4	
Ovr103X	Ovary 3	7	0.1
Ovr20GA	Ovary 4		0
5 Ovr25GA	Ovary 5		0

0 = Negative

Higher levels of expression were seen in prostate, showing a high degree of tissue specificity for prostate tissue. Of all the analyzed samples different from prostate, only two cancer samples (colon 2 with 116.97 and ovary 2 with 261.4), and 5 normal adjacent tissue samples (small intestine 2, colon 1, colon 2, kidney 1, and lung 2), showed an expression comparable to the mRNA expression in prostate. 15 These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 7).

Furthermore, the levels of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer (e.g. higher levels 20 of mRNA expression in the cancer sample compared to the normal adjacent). Table 8 shows higher expression of Pro115 in 3 out of 4 matched prostate cancer tissues (prostate samples 1, 5 & 8).

25 Altogether, the high level of tissue specificity, plus the higher expression in 75% of the prostate matching samples tested, are indicative of Pro115 being a diagnostic marker for prostate cancer.

Expression of Clone ID 3277219H1 (Pro110):

30 For the CSG Pro110, real-time quantitative PCR was performed using the following primers:

Forward Primer

5' - CGGCAACCTGGTAGTGAGTG - 3' (SEQ ID NO:29)

- 31 -

Reverse Primer

5' - CGCAGCTCCTTGTAAACTTCAG - 3' (SEQ ID NO:30)

The absolute numbers depicted in Table 9 are relative levels of expression of the CSG Pro110 in 12 normal different 5 tissues. All the values are compared to normal small intestine (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 9: Relative Levels of CSG Pro110 Expression in Pooled 10 Samples

Tissue	NORMAL
Brain	6.61
Heart	0.7
Kidney	0.74
Liver	7.94
Lung	11.88
Mammary	22.78
Muscle	6.77
Prostate	3.01
Small Intestine	1
Testis	2.58
Thymus	13.74
Uterus	2.61

The relative levels of expression in Table 9 show that Pro110 25 mRNA expression is not as high in normal prostate (3.01) compared with all the other normal tissues analyzed.

The absolute numbers in Table 9 were obtained analyzing pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers 30 originated from RNA obtained from tissue samples of a single individual in Table 10.

The absolute numbers depicted in Table 10 are relative levels of expression of Pro110 in 33 pairs of matching samples. All the values are compared to normal small 35 intestine (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from

- 32 -

the normal adjacent sample for that same tissue from the same individual.

Table 10: Relative Levels of CSG Pro110 Expression in Individual Samples

	Sample ID	Tissue	Cancer	Matching Normal Adjacent
5	Pro12B	Prostate 1	11.8	0.3
	Pro78XB	Prostate 2	14.3	6.3
	Pro101XB	Prostate 3	33.2	10.7
	Pro13XB	Prostate 4	0.3	0.4
	Pro23XB	Prostate 5	25.5	14.4
	Pro20XB	Prostate 6	43.3	4
	Pro34XB	Prostate 7	31.8	18.7
	Pro65XB	Prostate 8	26.9	3.4
	Pro69XB	Prostate 9	12.5	7
10	Lng75XC	Lung 1	1.9	3
	Lng90X	Lung 2	5.5	0.5
	LngAC11	Lung 3	9.3	9.7
	LngAC32	Lung 4	11.2	2.2
	Lng47XQ	Lung 5	11.3	0.3
	Lng60XL	Lung 6	29.1	6.8
15	Mam12B	Mammary Gland 1	19.8	0
	Mam603X	Mammary Gland 2	13.7	0
	Mam82XI	Mammary Gland 3	73.5	0
	MamA04	Mammary Gland 4	0	24.6
	MamB011X	Mammary Gland 5	17.4	2
	MamC012	Mammary Gland 6	0	12.8
	MamC034	Mammary Gland 7	0	61
	Mam12X	Mammary Gland 8	14	2.2
	Mam59X	Mammary Gland 9	33	2.2

- 33 -

MamA06X	Mammary Gland 10	16.4	0.8
Liv15XA	Liver 1	4.7	0.6
Liv42X	Liver 2	7.5	2.6
Liv94XA	Liver 3	0.4	1.4
5 ClnAS43	Colon 1	52.9	1.4
ClnAS45	Colon 2	2.1	0.8
ClnAS46	Colon 3	39.8	3.7
SmI21X	Small Intestine 1	0.9	0.1
SmIH89	Small Intestine 2	5.8	0.9

10 0 = Negative

The levels of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an indication of specificity for the cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 10 shows overexpression of Pro110 in 8 of the 9 primary prostate cancer tissues compared with their respective normal adjacent (except prostate 4). Thus, there was overexpression in 88.88% of the cancer prostate tissue 15 as compared to the prostate matching samples tested (total of 9 prostate matching samples).

20 Although not tissue specific, Pro110 mRNA expression is upregulated in prostate cancer tissues. The mRNA overexpression in 88.88% of the primary prostate matching 25 cancer samples tested is indicative of Pro110 being a diagnostic marker for prostate cancer. Pro110 also showed overexpression in several other cancers tested including small intestine, colon, liver, mammary and lung (see Table 10). Accordingly Pro110 may be a diagnostic marker for other types 30 of cancer as well.

- 34 -

Expression of Clone ID 1857415; Gene ID 346880 (Pro113):

For the CSG Pro113, real-time quantitative PCR was performed using the following primers:

Forward Primer

5 5' - CGGGAACCTACCAGCCTATG - 3' (SEQ ID NO:31)

Reverse Primer

5' - CAGGCAACAGGGAGTCATGT - 3' (SEQ ID NO:32)

The absolute numbers depicted in Table 11 are relative levels of expression of the CSG Pro113 in 12 normal different 10 tissues. All the values are compared to normal thymus (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

15 **Table 11: Relative Levels of CSG Pro113 Expression in Pooled Samples**

Tissue	NORMAL
Brain	0.03
Heart	0
Kidney	0.01
Liver	0
Lung	0
Mammary Gland	0
Muscle	0.04
20 Prostate	489.44
Small Intestine	0.02
Testis	0.35
25 Thymus	1
Uterus	0.13

The relative levels of expression in Table 11 show that Pro113 30 mRNA expression is higher (489.44) in prostate compared with all the other normal tissues analyzed. Testis, with a relative expression level of 0.35, uterus (0.13), thymus (1.0), kidney (0.01) and brain (0.03) were among the other tissues expressing lower mRNA levels for Pro113. These 35 results establish that Pro113 mRNA expression is highly specific for prostate.

- 35 -

The absolute numbers in Table 11 were obtained analyzing pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single 5 individual in Table 12.

The absolute numbers depicted in Table 12 are relative levels of expression of Pro113 in 78 pairs of matching and 25 unmatched tissue samples. All the values are compared to normal thymus (calibrator). A matching pair is formed by mRNA 10 from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In cancers (for example, ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were 15 analyzed.

Table 12: Relative Levels of CSG Pro113 Expression in Individual Samples

	Sample ID	Tissue	Cancer	Matched or Unmatched Normal Adjacent
20	Pro780B/781B	Prostate 1	375.58	446.29
	Pro1291B/1292B	Prostate 2	1060	31
	Pro139B96/140B96	Prostate 3	41	32
	Pro209B96/210B96	Prostate 4	505	255
	Pro1256B/1257B	Prostate 5	165.79	141.63
	Pro1293B/1294B	Prostate 6	1613.7	874.61
25	Pro694B/695B	Prostate 7	458.6	142.21
	Pro1012B/1013B	Prostate 8	1520	864
	Pro1222B/1223B	Prostate 9	939	530
	Pro845B/846B	Prostate 10	1552.4	374.6
	Pro1094B/1095B	Prostate 11	278.37	135.89
30	Pro650B/651B	Prostate 12	532.81	640.85

- 36 -

	Pro902B/903B	Prostate 13	609.05	415.86
	Pro916B/917B	Prostate 14	699.42	401.24
	Pro9821110A/110B	Prostate 15	156	487.8
	ProS9821326A/26B	Prostate 16	744.4	472.8
5	Pro9407c215	Prostate 17	1389.2	
	Pro9407c234	Prostate 18	305.5	
	Pro9407c280A	Prostate 19	894.5	
	Pro9409C010R	Prostate 20 (prostatitis)	269.7	
	Pro9404C120R	Prostate 21 (prostatitis)	299.2	
10	Pro1000258	Prostate 22 (BPH)	149.6	
	Pro4001263C	Prostate 23 (BPH)	576	
	Pro4001267A	Prostate 24 (BPH)	132.1	
	Pro9411C032	Prostate 25 (BPH)	118.2	
	Pro4001460Z	Prostate 26 (BPH)	276.3	
15	Pro4001271A	Prostate 27 (BPH)	58.7	
	Kid1064D/65D	Kidney 1	0	0.1
	Kid1079D/1080D	Kidney 2	0.3	0.02
	Kid1097D/1098D	Kidney 3	35.14	0.32
	Kid1024D/1025D	Kidney 4	1.31	0
20	Kid1183D/1184D	Kidney 5	24.79	0
	Kid1242D/1243D	Kidney 6	0	0
	Bld469K	Bladder 1		2.88
	Bld467K/468K	Bladder 2	2.65	
	Bld327K/328K	Bladder 3	0	4.05
25	Bld470K	Bladder 4		1.64
	Bld665T/664T	Bladder 5	0.21	1.99

- 37 -

	Bld1496K/1497K	Bladder 6	13.55	1.14
	Bld1721K/1722K	Bladder 7	120.16	1.34
	Tst239X/240X	Testis 1	31.5	0.73
	TstS9820647A/47B	Testis 2	15.7	0
5	TstS9820663A/663B	Testis 3	72	1.4
	SknS9821248A/248B	Skin 1	1.8	0.5
	SknS99448A/448B	Skin 2	251.6	0
	Skn99816A/816B	Skin 3	33	0.7
	Sto4004864A4/B4	Stomach 1	14.12	0
10	Sto4004509A3/B1	Stomach 2	40.74	39
	SmI9807A212A/213A	Small Intestine 1	0.1	0
	SmI9802H008/H009	Small Intestine 2	5.8	0.1
	Cln9608B012/B011	Colon 1	4.5	0
	Cln9709c074ra/073ra	Colon 2	65.8	3.1
15	Cln4004709A1/709B1	Colon 3	1.1	0.9
	Cln9405C199/C200	Colon 4	34.76	0.73
	Cln9707c004gb/006ga	Colon 5	90.26	0.96
	Cln96-09-B004/B003	Colon 6	17.9	20.64
	Cln9612B006/B005	Colon 7	17.56	0.3
20	Cln9705F002D/F001C	Colon 8	21.39	0
	ClnCXGA	Colon 9	429.14	142.69
	Pan10343a	Pancreas 1	0	0
	Pan776P/777P	Pancreas 2	0	0.15
	Pan9210/9220	Pancreas 3	7.36	0
25	Pan714L/715L	Pancreas 4	13.57	0.11
	Pan824P/825P	Pancreas 5	0	0
	Lng476Q/477Q	Lung 1	0	0
	Lng605L/606L	Lung 2	0	0.1
	Lng11145B/11145C	Lung 3	85.9	0

- 38 -

	Lng0008632A/32B	Lung 4	23.85	0
	Lng750C/751C	Lung 5	0.32	0.25
	Lng8890A/8890B	Lung 6	10.63	0
	Lng8926A/8926B	Lung 7	15.37	0
5	Lng0010239A/39B	Lung 8	26.17	0
	Lng9502C109R/110R	Lung 9	0.68	0
	LngS9821944a/44b	Lung 10	0	0
	Mam00042D01/42N01	Mammary Gland 1	8.5	0
	Mam59XC	Mammary Gland 2	61.07	0
10	Mam9706A066G/67C	Mammary Gland 3	4.84	0
	Maml4153a1C	Mammary Gland 4	9.72	6.99
	Maml620F/1621F	Mammary Gland 5	0.91	0
	Mam00014D05	Mammary Gland 6	2.45	0
	End10479B/D	Endometrium 1	133.43	1.12
15	End9705A125A/126A	Endometrium 2	0	0.39
	End9704C281A/282A	Endometrium 3	23.5	1.56
	End680o97/681o97	Endometrium 4	88.89	79.02
	Utr13590/13580	Uterus 1	0.2	0
	Utr850U/851U	Uterus 2	0	0
20	Utr14170/14180	Uterus 3	14	0.4
	Utr233U96/234U96	Uterus 4	8.65	4.64
	CvxVNM00052D01/52N01	Cervix 1	0.82	77.15
	CvxVNM00083D01/83N01	Cervix 2	0.78	221.48
	CvxND00023D01/23N01	Cervix 3	3.25	15.22
25	Ovr10370/10380	Ovary 1	0.1	0
	Ovr10050	Ovary 2	18.96	
	Ovr1028	Ovary 3	0	
	Ovr14638A1C	Ovary 4	3.2	
	Ovr14603A1D	Ovary 5	882.3	
30	Ovr7730	Ovary 6	0	

- 39 -

Ovr9702C018GA	Ovary 7		0.15
Ovr206I	Ovary 8		0
Ovr9702C020GA	Ovary 9		0
Ovr9702C025GA	Ovary 10		0
5 Ovr9701C035GA	Ovary 11		0.07
Ovr9701C050GB	Ovary 12		0.58

0 = Negative

In the analysis of matching samples, the higher levels of expression were in prostate, showing a high degree of 10 tissue specificity for prostate tissue. In addition to the higher expression levels in prostate cancer samples, Pro113 expression was found to be either induced (where not expressed in normal adjacent tissues) or somewhat upregulated in several other cancers. However, the relative expression and the fold 15 increase in prostate cancer samples far exceeds that in other cancer tissues and is highly significant.

Furthermore, the levels of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an 20 indication of specificity for the cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 12 shows overexpression of Pro113 in 13 out of 16 primary prostate cancer tissues compared with their respective normal adjacent (prostate samples 2, 3, 4, 5, 6 7, 25 8, 9, 10, 11, 13, 14, 16). Thus, there was overexpression in the cancer tissue for 81.25% of the prostate matching samples tested. The median for the level of expression in prostate cancer tissue samples is 609, whereas the median for all other cancers is only 7.93, with the exception of one colon sample, 30 colon 9, whose expression was similar to that found in prostate cancer tissues.

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 81.25% of the primary prostate matching samples tested are indicative of Pro113 being a

- 40 -

diagnostic marker for prostate cancer. Expression was also found to be higher in other cancer tissues compared with their respective normal adjacent tissues (kidney, bladder, testis, skin, stomach, small intestine, colon, pancreas, lung, 5 mammary, endometrium, uterus, and ovary) thus indicating Prol13 to be a pan cancer marker.

Expression of Clone ID 1810463H1 (Prol14):

For the CSG Prol14, real-time quantitative PCR was performed using the following primers:

10 Forward Primer

5' - TGGGCATCTGGGTGTCAA - 3' (SEQ ID NO:33)

Reverse Primer

5' - CGGCTGCGATGAGGAAGTA - 3' (SEQ ID NO:34)

15 The absolute numbers depicted in Table 13 are relative levels of expression of the CSG Prol14 in 12 normal different tissues. All the values are compared to normal muscle (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

20 **Table 13: Relative Levels of CSG Prol14 Expression in Pooled Samples**

Tissue	NORMAL
Brain	9.7
Heart	0.7
Kidney	414.4
Liver	4
Lung	882.2
Mammary	44
Muscle	1
Prostate	1951
Small Intestine	22
Testis	367.1
Thymus	25.8
Uterus	139.6

35 The relative levels of expression in Table 13 show that Prol14 mRNA expression is higher (1951) in prostate compared with all the other normal tissues analyzed. Lung, with a relative

- 41 -

expression level of 882.2, kidney 414.4, testis 367.1 and uterus 139.6, are the other tissues expressing higher levels of mRNA for Pro114. These results establish Pro114 mRNA expression to be more specific for prostate than other tissues
5 examined.

The high level of tissue specificity is indicative of Pro114 being a diagnostic marker for diseases of the prostate, especially cancer.

Expression of Clone ID zr65g11 (Pro118):

10 For the CSG Pro118, real-time quantitative PCR was performed using the following primers:

Forward Primer

5' - GCCCATCTCCTGCTTCTTAGT - 3' (SEQ ID NO:35)

Reverse Primer

15 5' - CGTGGAGATGGCTCTGATGTA - 3' (SEQ ID NO:36)

The absolute numbers depicted in Table 14 are relative levels of expression of the CSG Pro118 in 12 normal different tissues. All the values are compared to normal kidney (calibrator). These RNA samples are commercially available
20 pools, originated by pooling samples of a particular tissue from different individuals.

Table 14: Relative Levels of CSG Pro118 Expression in Pooled Samples

Tissue	NORMAL
Colon	0.87
Endometrium	19282
Kidney	1
Liver	0
Ovary	86.22
Pancreas	0
Prostate	962.1
Small Intestine	0
Spleen	0.75
Stomach	0.54
Testis	343.7
Uterus	1064

- 42 -

The relative levels of expression in Table 14 show that Pro118 mRNA expression is the 3rd highest in prostate (962.1) next to endometrium (19282) and uterus (1064), which are female-specific tissues. Testis, with a relative expression 5 level of 343.7 is the only other male tissue expressing moderate levels of mRNA for Pro118. These results establish Pro118 mRNA expression to be highly specific for reproductive tissues including the prostate.

The absolute numbers in Table 14 were obtained analyzing 10 pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 15.

The absolute numbers depicted in Table 15 are relative 15 levels of expression of Pro118 in 59 pairs of matching and 21 unmatched samples. All the values are compared to normal kidney (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same 20 individual.

Table 15: Relative Levels of CSG Pro118 Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal Adjacent
Pro12B	Prostate 1	41700.7	22242.83
ProC234	Prostate 2	40087	
Pro78XB	Prostate 3	4075.6	7066.7
Pro109XB	Prostate 4	334.4	777.2
Pro84XB	Prostate 5	11684	.58290
Pro101XB	Prostate 6	21474.13	100720.8
Pro91X	Prostate 7	14849	33717
Pro13XB	Prostate 8	202.57	146.91

- 43 -

	Proc215	Prostate 9	73243	
	Pro125XB	Prostate 10	629.6	521.4
	Pro23B	Prostate 11	157532.6	110654.4
	Pro90XB	Prostate 12	2317	64134
5	Proc280	Prostate 13	42020	
	Pro20XB	Prostate 14	2909.31	
	Pro34B	Prostate 15	29610	23264
	Pro110	Prostate 16	13354	30991
	Pro65XB	Prostate 17	10126	11270
10	Pro69XB	Prostate 18		2671.42
	Pro326	Prostate 19	9962.3	19231
	Pro10R	Prostate 20 (prostatitis)	27355	
	Pro20R	Prostate 21 (prostatitis)	21081	
	Pro258	Prostate 22 (BPH)	79916.32	
15	Pro263C	Prostate 23 (BPH)	108924.5	
	Pro267A	Prostate 24 (BPH)	92910.22	
	Pro271A	Prostate 25 (BPH)	57004.4	
	Pro460Z	Prostate 26 (BPH)	57449.23	
	ProC032	Prostate 27 (BPH)	45781.44	
20	Kid106XD	Kidney 1	3.08	217.36
	Kid107XD	Kidney 2	0	38.36
	Kid109XD	Kidney 3	0	123.5
	Kid10XD	Kidney 4	17.69	67.8
	Kid11XD	Kidney 5	16.74	360.8
25	Kid124D	Kidney 6	0	167.4
	Bld32XK	Bladder 1	0	0
	Bld47K	Bladder 2		36.38
	Bld66X	Bladder 3	0	4.52
	BldTR14	Bladder 4	0	12.17

- 44 -

	BldTR17	Bladder 5	0	0
	Bld46XK	Bladder 6	16.5	0
	Tst39X	Testis 1	116.6	24.35
	Tst647T	Testis 2	856.16	43.5
5	StoAC44	Stomach 1	0	0
	StoAC93	Stomach 2	0	0
	SmI21XA	Small Intestine 1	68.45	0
	SmIH89	Small Intestine 2	0	0
	ClnAC19	Colon 1	149	21.33
10	ClnAS12	Colon 2	0	0
	ClnB34	Colon 3	0	0
	ClnB56	Colon 4	13.04	5.22
	ClnAS43	Colon 5	0	0
	Lng47XQ	Lung 1	0	0
15	Lng60XL	Lung 2	0	0
	Lng75XC	Lung 3	0	3.38
	Lng90X	Lung 4	0	0
	LngBR26	Lung 5	0	26.82
	Pan10343	Pancreas 1	50.47	0
20	Pan77X	Pancreas 2	281.1	0
	Pan92X	Pancreas 3	18.41	0
	Pan71XL	Pancreas 4	0	0
	Pan82XP	Pancreas 5	0	0
	PanC044	Pancreas 6	0	0
25	Mam12X	Mammary Gland 1	0	0
	Mam162X	Mammary Gland 2	0	0
	Mam42DN	Mammary Gland 3	0	0
	MamS127	Mammary Gland 4	12.58	0
	Mam14DN	Mammary Gland 5	0	0
30	End28XA	Endometrium 1	331.9	1824

- 45 -

End3AX	Endometrium 2	27825	65839
End4XA	Endometrium 3	10.3	15935
Utr141O	Uterus 1	18885	18116
Utr23XU	Uterus 2	3358	7674
5 CvxKS52	Cervix 1	0	0
CvxKS83	Cervix 2	0	0
Ovr10050	Ovary 1	72.86	
Ovr1028	Ovary 2	0	
Ovr638A	Ovary 3	0	
10 Ovr63A	Ovary 4	90.88	
Ovr773O	Ovary 5	1.21	
Ovr10400	Ovary 6	5.08	
Ovr1050	Ovary 7	0	
Ovr1118	Ovary 8	7.41	
15 Ovr103X	Ovary 9		32.78.
Ovr20GA	Ovary 10		0
Ovr25GA	Ovary 11		1173.83
Ovr35GA	Ovary 12		313.4
Ovr50GB	Ovary 13		823.1
20 Ovr18GA	Ovary 14		40.6
Ovr206I	Ovary 15		1264
Ovr230A	Ovary 16		1285

0 = Negative

In the analysis of matching samples, the higher levels of expression were in prostate, endometrium, testis, and ovary showing a high degree of tissue specificity for reproductive tissues. These results confirmed the tissue specificity results obtained with the panel of normal pooled samples (Table 14).

Furthermore, the levels of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were compared. This comparison provides an

- 46 -

indication of specificity for the cancer (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent). Table 15 shows overexpression of Pro118 in 5 out of 14 primary prostate cancer tissues (prostate samples 1, 8, 5 10, 11, 15) compared with their respective normal adjacent. Thus, there was overexpression in the cancer tissue for 35.71% of the prostate matching samples tested (total of 14 prostate matching samples). Expression of Pro118 was similarly higher in 10 3 unmatched cancer tissues (prostate samples 9, 13, 14), 15 2 prostatitis (prostate samples 20, 21), and 6 benign hyperplasia tissues (prostate samples 22 through 27).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in 35.71% of the primary prostate matching samples tested are indicative of Pro118 being a 15 diagnostic marker for prostate cancer.

- 47 -

What is claimed is:

1. A method for diagnosing the presence of prostate cancer in a patient comprising:
 - (a) determining levels of CSG in cells, tissues or bodily fluids in a patient; and
 - (b) comparing the determined levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of CSG in said patient versus normal human control is associated with the presence of prostate cancer.
2. A method of diagnosing metastases of prostate cancer in a patient comprising:
 - (a) identifying a patient having prostate cancer that is not known to have metastasized;
 - (b) determining CSG levels in a sample of cells, tissues, or bodily fluid from said patient; and
 - (c) comparing the determined CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.
3. A method of staging prostate cancer in a patient having prostate cancer comprising:
 - (a) identifying a patient having prostate cancer;
 - (b) determining CSG levels in a sample of cells, tissue, or bodily fluid from said patient; and
 - (c) comparing determined CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined CSG levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined CSG levels is associated with a cancer which is regressing or in remission.

- 48 -

4. A method of monitoring prostate cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having prostate cancer that is not known to have metastasized;

5 (b) periodically determining levels of CSG in samples of cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the 10 periodically determined CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring a change in stage of prostate cancer in a patient comprising:

15 (a) identifying a patient having prostate cancer;

(b) periodically determining levels of CSG in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal 20 human control, wherein an increase in any one of the periodically determined CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

25 6. A method of identifying potential therapeutic agents for use in imaging and treating prostate cancer comprising screening molecules for an ability to bind to CSG wherein the ability of a molecule to bind to CSG is indicative of the molecule being useful in imaging and treating prostate cancer.

30 7. The method of claim 1, 2, 3, 4, 5 or 6 wherein the CSG comprises SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,

- 49 -

13, 14, 15, 16, 17, 18, 19 or 20 or a polypeptide encoded thereby.

8. An antibody which specifically binds CSG.

9. A method of imaging prostate cancer in a patient
5 comprising administering to the patient an antibody of claim
8.

10. The method of claim 9 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

11. A method of treating prostate cancer in a patient
10 comprising administering to the patient an antibody of claim
7.

12. The method of claim 11 wherein the antibody is conjugated to a cytotoxic agent.

SEQUENCE LISTING

<110> Salceda, Susana
Recipon, Herve
Cafferkey, Robert
diaDexus, LLC

<120> Method of Diagnosing, Monitoring, Staging, Imaging and
Treating Prostate Cancer

<130> DEX-0052

<140>
<141>

<150> 60/104,737
<151> 1998-10-19

<160> 36

<170> PatentIn Ver. 2.0

<210> 1
<211> 188
<212> DNA
<213> Homo sapiens

<400> 1
ggtaaacacc tgctttatc atcagaacaa agaggctgtg tccctgtccc tatgaggtcc 60
atttctgaga gttgtggcta atggcaaga aggtggggc ttttagagatt tggataaag 120
atataacaaca ccagaaaggt agaaaagaagt gatcagatta ggttactta ggtgatgata 180
tgaactct 188

<210> 2
<211> 9819
<212> DNA
<213> Homo sapiens

<400> 2
cagctgggt ctacccaggt ccatgttttg gacatgttga gagttttctt ggaaggcagg 60
gatacagtgt ggtccaaaaa cacacaaatg cccctactgg cccagggggtt gtcacaatag 120
actggaaaggg tgacacatcc caggcgcttg ccacccatca cacgcacctc ctacccactg 180
gcataccttcc accccaggca cacacaaagc ctcagttccag agatcaactc tggactcagc 240
tctgaatttg catacttgtt gtgttagattt attcttcata acctctgtccc agccttagctt 300
gtgtatcatt tttttttctc tatttaggggaa ggagcccgcc ctggcactcc cattggcctg 360
tagattcacc tccctgggc agggccccag gacccaggat aatatctgtg cctcctgtccc 420
agaaccctcc aagcagacac aatggtaaga atggtcctg tcctgtgtc tctgtgtctg 480
cttctgggtc ctgtgtcccc ccaggagaac caagatggtg agtggggaaa gcaagggatg 540

gggttcatgc cattctcctg cctcagcctc ctgagtagct gggactacag gcacccgcca 3480
 ccatgcttgg ctaatttttta gaattcttag tagagacggg gtttcacccat gttagccagg 3540
 atggctcga ttcctgacc tcgtatcca cccgcctcgg cccccctaaag tgctgggatt 3600
 acaggcgtga gccactgagc ccggacgaaa tgtaatttgc ttttttttgc gacggagtct 3660
 cactctgtca tccaaagctgg agtgcagtgg catgatcttgc gcttgcata acctctgcct 3720
 ctctgggtca agtgcatttc ctgcctcagc ctccagcatg actgggatca caggccccca 3780
 ccacccatgcc cagctaattt ttgtatccata taatagagat ggggtttcac catgttggcc 3840
 aggctggctc tcaactcctg atctcaagta atctgcctgc cttggccccc caaagtcctg 3900
 ggattacagg catgagccac ggagcccccctg ctagaaatgt taatccataa cgcatgtcag 3960
 attccatgca cactgggca ggttccatcc ctccatgggg tgactcaggat atccaggcca 4020
 attgcatttgc gggactcttgc catattatcc tggcccttc aaagtcgtca cctctaggga 4080
 tgagaaacaa aaggggaaagc cagctggtag ggtcttggac aagaagaaaag acatcaattc 4140
 tgctcacatt ctcttttgc aaaaactcagt cacatggcc caatataatct tcgaggtggc 4200
 tgagtaatgt tatcttcata tggcataaggc agagggaaata atgttagtggaa gacacaggat 4260
 ggtctctgaa atatcatctc aggcatgaaa gtagagcata ttcacttgc tgagcctcca 4320
 gtgggtgtgaa gttgatggca ggagaaagag ctggggaga aaggccagg ggcaggtctc 4380
 ccctccatgc cctatgcagc cccacatgg gacccttgc tggacccatca ccatcagaat 4440
 cttttttttgc caggtcgatc actctctgac ctatatactac actgggctgt ccaagcatgt 4500
 tgaagacgtc cccgcgtttc agggcccttgc ctcactcaat gacccatcact tcttttagata 4560
 caacagtaaa gacagggaaatc ctcagccat gggactctgg agacagggtgg aaggaatgg 4620
 ggattggaaag caggacacggc aacttcagaa ggccaggggag gacatcttgc tggagaccc 4680
 gaaagacatt gttggatcatt acaacgcacag taacggcgtc tgaataacag accacagggg 4740
 tggaaaggctc aacccaaagag gcaagcccccc cagttgtggat ggcacaggat cagcaggatg 4800
 gaaatagtcc caatcccagg ggaagaacacag gagacacacgc agaaacacacag acatgtccgc 4860
 atccccacccca ccccacacgc cagggtcgatc ccgttccccc atcaatttgc ccatcctcat 4920
 cccaggcctc agtgcacaca ggaagtgtatc gcaaggtcact ttcctatcca ggcacccatg 4980
 acctctcacc tccacaccccccc acccatcgga ggctgtatacc cccgtggatggaa ggcacccatg 5040
 tcacccctgt ccaggggaggt tggctggaga gtggccact ctcaaaatgtca ctcagaccc 5100
 ggctcacctg tgggttctgc cagtccttgc tggatcact gaaacgttcc caaaatatct 5160
 ggttggaaatc tgcaaacatt ggagcactga gacccatc caaacaatgtc tgtaatattt 5220
 aactatgtct gttctatgaa ggatgtcaca gtctgtccctg atctcccttgc cagctccatc 5280
 accttagcaca gggtagcagcc aatattggct caattggaaat ttgtggaaatc cacagagaaa 5340
 agcaccggc acacaccgtt gcccattgtc ggggtcagg aagtgtggatc ttcaaaactg 5400
 tgggtgttta ggttcccttgc gggccctaaa gttcccttgc accatacgtt gcaagaccatg 5460
 gaagggccac ctgcgtatgc gtcagaggag ctgggtggcag agcccgatgc gagatggtcc 5520
 ctgtggccccc gggccactgtc tctttcttgc aaaccacact gcccggccca aggcagccaa 5580
 cctcaggctc ggtgaactgtc tgggtgtttaaa ttatcataga tgggtgttgc aaagatgggc 5640
 tactaagtac aaaaatgtccc aaggtgttgc atggatcttgc aagatccatc aaaggagggca 5700
 agaaagagat aggcagatgt ttcaaggatg tgggtgggg gagggtcttgc taaggaaaat 5760
 gggccaggct gttgttgcagc aataggagag gggggggcactt gaggatgttgc aaaaagacact 5820
 gggggaaagca ttgtatggaca ggaatagaaa tggcaaaatgt gataatggaa aggaaggagg 5880
 atgaggagat gaacacacggg tattagaaaa taatagaagg cagggttgc tggctactc 5940
 ttgtatcccccc agcactttgg gagggttgc gagggttgc accttgc gggatgttgc 6000
 gaccaggcccg gccaacatgg tggatggatc tcttgcacttgc taatataaaaa atagcctggc 6060
 atgggtggcacttgc acgttgcgttgc tccatgttgc tcaaggatgttgc gagggttgc aattgttgc 6120
 acccaggagg cagggatgttgc agtggccaaa atccttgcacttgc tggatggatc gggatgttgc 6180
 aagatgttgc aatgttgcataa aacaaaaaaa caaaaaacaaa aaaaaggaaa taatgttgc 6240
 tgacatttgc tggatggatc tggatggatc tggatggatc tggatggatc tggatggatc 6300

aatagccccc taaaacagtg ctcttggcat tgccattca gaggtgagga aatagaggca 6360
 cagggagttg agtggctcca gttcaggcaa cacaccagg gggggtgggg ggctggggag 6420
 agacctggga cgtgagccca gacagcttga gagcttcag agtctatgcc aacagcacca 6480
 accagtgtg ggtaaacacc tgcttttatac atcagaacaa agaggctgtg tccccctgccc 6540
 tatgagggtcc atttctgaga gttgtggcta atggcaaga agttggggc ttttagagatt 6600
 tgggataaaag atatcaaaca ccagaaaggt agaaaagaat gatcagatta gggttactta 6660
 ggtgtatgata tgaactctt ctagaactga gagaaaaaga gageccttctt ttactcatat 6720
 gaaatcacaa ataatttcta tccaatttgg aagtacactt tggtgttagtt gtgacagctt 6780
 cctcaggact cagcataaaat tcaaacaat aattgtcctt agaagagatg ctatagaaga 6840
 gatagaaata tattcatatt ctgtagctt tttttttt agatggagtt ttgtcttctgt 6900
 cacccaaagct ggagtgcagt gatgcaatct cagctcaactg caaactttgc ctccctgggtt 6960
 caagggatcc tcctgcctca gcctcccgat aactggact acaggctaca ggcatgtgtc 7020
 actactctt gttatttttt tttttttttt tttaagactg agtcttgc tttttttttt 7080
 gctgtatgtac aatggcttca ttcggctca ctacaacttc tgccccccag gttcaagcga 7140
 ttcttcgtcc tcagectcat gagtagctgg gattacaggc atgtgccagc acacccagca 7200
 aatttttta ttttttagtag agatgaggctt ttaccatgtt ggcaggctg gtctcaaact 7260
 cctgacctca ggtgtatcctt tggcctcagc ctcccttaact gctgggatttta caggcatgag 7320
 ccactgegtc cagcctaattt ttatattttt ggttagagatg gggtttccacc atattggcca 7380
 ggctggcttc gaactcatga cctaaggta tccatccctcc tcagcctctc aaagtgttgg 7440
 gattacaatg gtgagccact gggcctggg cttttttttt tttttttttt tttttttttt 7500
 tgagataggg tctcaactctg tcacccaggc tgaaatgcag tagtgtgatt ttggcttcat 7560
 gcagccttga cttcccaggc tgaagtgtc tcccccacctc agcctcttgc gtagctgggg 7620
 ctacaggcat gcaccaccat gctgcgtttaa tttttatatt ttttttagtgg gttggatttc 7680
 gccatatacac cctggcttggt ctggaaacccc tgggctcaag cgatccactc gcttcagctt 7740
 ctcaaaatgtc tgggattaca ggcattgagcc acagcgttca ggcgtgtatgt ctcttaagga 7800
 ggaacatatac tcatactgaga caaaacctgaa atgccaacc aactgtatgtt agccccctctc 7860
 tgtctgttgt atatatttggta gtaataatctt atttgtcttgc ataaaaggat tgcattgttgc 7920
 aatttgcaaaa acctttatattt cttttgggtt gccaaatgtc caagactaag agttatttt 7980
 ataaaatttctt caccaggctg actgtctctc tttttttttt cagggcttca 8040
 cgttattgtcag ggaaggtttg gttgttagat cgagaataac agaaggcagcg gaggattctg 8100
 gaaatattac tatgtatggaa aggactacat tgaattcaac aaagaaatcc cagcctgggt 8160
 ccccttcgac ccagcagccc agataaccaa gcagaagtgg gaggcagaac cagtctacgt 8220
 gcagcgggccc aaggcttacc tggaggaggc gtgcctgtcg actctgtcgaa aataacctgaa 8280
 atacagcaaa aatatccctgg accggcaagg tactcaactgc ttctctgtcc ccagttactga 8340
 gcccagaata aaagacgtatc tcaggctagg agtcaggca acatcttagt ccggctctcat 8400
 ctgttccctgg atgtccctca gaccccccagg tttcatctt tagattttt cccttccctg 8460
 ggataatata atttgtggtc caaaaagaac atcatcaaaa tttcaggcag aatggggccag 8520
 gaaggccatt ctttcttgat gagtgccccca aaatcatctc caattaacag acaaggagct 8580
 tgagggtttagg gaggtgaggg taacactgtc tgtaagaggc agagctggga ctcaaaattcc 8640
 agatttcaga ttccaaatcc catcgttttt tatctctaca atgtgcctc ccattctgggt 8700
 ggtggagaga agggaggcgt gtaaaagtca gccccagaag gacaagagca agccagtgtg 8760
 agcggaaattt atggctgttca gctgagactt ggattggaga cgtgtgttgc ctcaggattt 8820
 tgcagtgtcg caggaaagtgg tttgtggat agaggcatgg gctgaaccaa gcagctggac 8880
 tgagacttttgggg ggacagaact ccaagccca ctgagatgtg ggaaaacatg gagaaggcaca 8940
 cggagcattt cacaacttattt gcccgtcaggag tcaatacatg ggtgagggtgg ggattgggca 9000
 agagggaaag cgtcagctt ccctgtatattt ctggaaagtc tcccccggctt ggggggtggggc 9060
 aggtacagag ctgcagctc tgctgtatgtc tgacatccag ggggtgggggtt aggaagagac 9120
 ctggggccggg agaagtccac ctcaagcctg cagtgtcaca ctctatccctt ccacagatcc 9180

tccctctgtg gtggcacca gccaccagc cccaggagaa aagaagaaac tgaagtgcct 9240
 ggcctacgac ttctacccag gaaaaatga tgtgcactgg actcgggccc gcgaggtgca 9300
 ggagcctgag ttacggggag atgttctca caatggaaat ggcacttacc agtcctgggt 9360
 ggtgggtggca gtgccccccgc aggacacagc cccctactcc tgccacgtgc agcacagcag 9420
 cctggcccg cccctctgtgg tgccctggga ggccagctag gaagcaaggg ttggaggcaa 9480
 tgtggatct cagacccagt agctgccctt cctgcctgat gtggagctg aaccacagaa 9540
 atcacagtca atggatccac aaggcctgag gagcagtgtg gggggacaga caggaggtgg 9600
 atttggagac cgaagactgg gatgcctgtc ttgagtagac ttggacccaa aaaatcatct 9660
 cacattgagc ccaccccccac cccattgtct aatctgtaga agctaataaaa taatcatccc 9720
 tccttgctta gcataacaga gaatcccttt ttaacggtg atgcgtgt aaaaatgtgac 9780
 tagattttct cattggttct gcccctaagc actgaattc 9819

<210> 3

<211> 250

<212> DNA

<213> Homo sapiens

<400> 3

cgccccctgcg ccgcccggcc agctgccaga atgccaact ggggaggagg caagaaatgt 60
 ggggtgtgtc agaagacggt ttactttgcc gaagagggttc agtgcgaagg caacagcttc 120
 cataaatctt gcttctgtg catggctgc aagaagaatc tggacagttac cactgtggcc 180
 gtgcattgtg aggagattt ctgcaagtcc tgcacggca agaagtatgg gcccggcc 240
 tatggctacg 250

<210> 4

<211> 1900

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (16)

<220>

<221> unsure

<222> (18)

<220>

<221> unsure

<222> (20)

<220>

<221> unsure

<222> (1887)

<220>

<221> unsure

<222> (1894)

<400> 4

acgccttccg cgagnanan caaaaacggcg cgcaaggccgg ggcacccag cggccacttc 60
 cgagagcgc tggcccccgg ggcgcggc agccagctgc cagaatgccg aactggggag 120
 gaggcaagaa atgtggggtg tgtcaagaag acggttact ttggcgaaga ggttcagtgc 180
 gaaggcaaca gcttccataa atcctgcttc ctgtgcatgg tctgcaagaa gaatctggac 240
 agtaccactg tggccgtgc atggtgagga gatttactgg caagtccctg ctacggcaag 300
 aagtatgggc ccaaaggcta tggctacggg ccagggcga ggcacccctca gcactgacaa 360
 gggggagtgc ctgggtatca agcacgagga agccctggg ccacagggcc accaccaacc 420
 ccaatggcat ccaaatttgc ccagaagatt ggtggctccg agcgctgccc cggatgcagc 480
 caggcagtct atgctgcgga gaaggtgatt ggtgtggga agtcttggca taaggcctgc 540
 ttgcgtgtg ccaagtgtgg caaaggctt gactcaacca ccctggcag acaaggatgg 600
 cgagatttac tgcaaaggat gttatgtcaa aaacttccggg cccaagggtt ttggtttgg 660
 gcaaggagct gggcccttgg tccactctga gtgaggccac catcacccac cacacccctgc 720
 ccactcctgc gctttcattt gccatttccat tcccagcage tttggagacc tccaggatta 780
 tttctctgtc agccctgcacatcatca atgacttggaa ctggggcatc tggctccctt 840
 tgggtttgggg gtctgcctga ggtcccaccc cactaaagggg ctcccccagge ctgggatctg 900
 acaccatcac cagtaggaga cctcagtgtt ttgggtcttag gtgagagcag gcccccttc 960
 ccacacctcg ccccacagag ctctgttctt agccttctgt gctgcgtgtc catcatcagc 1020
 tgaccaagac acctgaggac acatcttgc acccagagga gcagcagcaa caggctggag 1080
 ggagagggaa gcaagaccaa gatgaggagg ggggaaggct gggtttttg gatctcagag 1140
 attctctct gtgggaaaga ggtttagctt cctgggtgtcc ctcagagtaa gcttgaggag 1200
 tcccagcttta gggagttcac tattggaggc agagaggcat gcaggcaggg tccttaggagc 1260
 ccctgttctt ccaggccctt tgcctttgag tctttgtgaa atggatagcc tcccacttagg 1320
 actgggagga gaataaccca ggtcttaagg accccaaagt caggatgtt tttgatcttc 1380
 tcaaacatct agtccctgc ttgtatggag gatcctaattt aaataacttga aacatataatt 1440
 ggcatttttc aatggctcaa atcttcattt atctctggcc ttaacccctgg ctcctgaggc 1500
 tgcggccagc agagcccagg ccaggctt gttttggcca cacctgctt atcctcagat 1560
 gtggagggag gtaggcactg ctcagttt catccaaaca cctttccctt tgccctgaga 1620
 cctcagaatc ttccctttaa cccaaagaccc tgccttgc actccaccc tctccaggga 1680
 cccttagatc acatcaactcc accccctgcca ggccccaggt taggaatagt ggtgggagga 1740
 aggggaaagg gctgggcctc accgctccca gcaactgaaa ggacaacact atctggagcc 1800
 acccactgaa agggctgcag gcatggctg tacccaaagct gatttctcat ctggtaata 1860
 aagctgttta gaccagaaaa aaaaaanaaaa aaanaaaaagg 1900

<210> 5

<211> 273

<212> DNA

<213> Homo sapiens

<400> 5

gatgcataa aagagctgca agtttccac attgacttct tgaatcagga caacgccgtt 60
 tctcaccaca catggagtt ccaaaccgagc agtcctgtgt tccggcgagg acaggtgtt 120
 cacctgcggc tgggtgtgaa ccagccctta caatccatcc accaactgaa actggaaattc 180
 agcacagggc cgaatccatg catgcacaa cacaccctgg tgggtgtcga cccgaggacg 240
 ccctcagacc actacaactg gcaggcaacc ctt 273

<210> 6

<211> 3021

<212> DNA

<213> Homo sapiens

<400> 6

tgtggaagca ccaggcatca gagatagagt cttccctggc attgcaggag agaatctgaa 60
gggatgatgg atgcatcaa agagctcaa gttctccaca ttgacttctt gaatcaggac 120
aacgccgtt ctcaccacac atgggagttc caaacgagca gtcctgtgtt ccggcgagga 180
caggtgttcc acctgcggct ggtgctgaac cagccccatc aatccatcca ccaactgaaa 240
ctggaaattca gcacaggggcc gaatcttagc atgcacaaac acacccctggt ggtgctcgac 300
ccgaggacgc cctcagacca ctacaactgg caggcaaccc ttcaaaaatga gtctggcaaa 360
gaggtcacag tggctgtcac cagttcccc aatgcccattc tgggcaagta ccaactaaac 420
gtgaaaactg gaaaccacat ccttaagtct gaagaaaaca ttctataacct tctttcaac 480
ccatggtgta aagaggacat ggtttcatg cctgatgagg acgagcgcaa agagtacatc 540
ctcaatgaca cgggctgcca ttacgtgggg gctgccagaa gtatcaaattg caaaccctgg 600
aactttggtc agttttagaa aaatgtctg gactgctgca ttccctgtc gactgagagc 660
tccctcaagc ccacagatag gaggggacccc gtgtgtgtt gcaggggccat gtgtgtatg 720
atgagctttg agaaaggcca gggcgtgctc attgggattt ggactggggc ctatgaaggt 780
ggcacagccc catacaagtg gacaggcagt gccccatcc tgcagcagta ctacaacacg 840
aagcaggctg tggctttgg ccagtgttgg gtgtttgttgg ggatcctgac tacagtgttgg 900
agagcgttgg gcatccacac acgcagtgac acaggcttgc attcagctca cgacacagaa 960
aggaacctca cggtgacac ctatgtaat gagaatggca agaaaatcac cagtatgacc 1020
caegactctg tctggaaattt ccatgtgtgg acggatgcct ggatgaagcg accggatctg 1080
cccaagggtt acgacggctg gcagggtgtt gacgcaacgc cgcaggagcg aagccagggt 1140
gtcttctgtt gttggccatc accactgacc gcccattcgca aaggtgacat ctttattgtc 1200
tatgacacca gattcgtctt ctcagaatgt aatgttgaca ggctcatctg gttgggtgaag 1260
atggtaatg ggcaggagga gttacacgtt atttcaatgg agaccacaag catcgggaaa 1320
aacatcagca ccaaggcagt gggccaagac aggccggagag attacacca ttagtacaag 1380
tatccagaag gtcctctga ggagaggcag gttcatggat catgccttcc ttccctctcag 1440
ttctgagagg gaggcacagac gacctgtaaa agagaacttt cttcacatgt cggtacaatc 1500
agatgatgtt ctgctggaa actctgtttaa ttccacccgtt attctttaaaa ggaagacccg 1560
tgccttacag aatgtcaaca tcttgggttc ttgttgaacta cagttgtaca ctggcaagaa 1620
gatggcaaaa ctgtgtgacc tcaataagac ctgcagatc caaggtcaag tatcagaagt 1680
gactctgacc ttggactcca agacccatc caacagcctg gctatattag atgatgagcc 1740
agttatcaga ggttcatca ttgcggaaat tggggatctt aaggaaatca tggcctctga 1800
agtattcagc tctttccatg accctgagtt ctctatagag ttgccttaca caggcagaat 1860
tggccagctt cttgtctgca attgtatctt caagaatacc ctggccatcc ctttgactga 1920
cgtcaagtcc tctttggaaa gcctggcat ctccttacta cagacccatc accatgggtg 1980
agtctgttgc aggcgggtgc agcctggta gaccatccaa tcccaaataa aatgcaccc 2040
aataaaaatg gacccaagaa atttategtc aagttaaatg ccaaaacaatg gaaagagatt 2100
aatgctcaga agattgttctt catcaccaag tagccttgc ttagtgcgtt gagectttagt 2160
tgagatttca gcatttccat cttgtggct tagctttagt attatggatg attaaatgg 2220
atgacttata tgagggcaga ttcaagagcc agcaggtaaa aaaggccaaac acaaccataa 2280
gcagccagac ccacaaggcc aggtcctgtt ctatcacagg gtcacccctt tttacagtt 2340
gaaacaccag ccgaggccac agaattccat cccttccatg agtcatggcc tcaaaaatca 2400
gggccaccat tggctcaatt caaatccata gatttcaag ccacagattc tctccctgg 2460
gcaagcatga ctatggccag cccagtgctt ccacccatg acgacccttg agaagctgcc 2520
atatcttcaatg gcatgggtt caccagccctt gaaggccat gtcacttgc gttgtctctc 2580

agcactggga tgggcctgat agaagtgcata tctccctcta ttgcctccat tctccctctct 2640
 ctatccctga aatccaggaa gtcccctctcc tggtgctcca agcagtttga agcccaatct 2700
 gcaaggacat ttctcaaggg ccatgtggtt ttgcagacaa ccctgtccctc aggectgaac 2760
 tcaccataga gaccatgtc agcaaacggt gaccagcaaa tcttcttccc ttattctaaa 2820
 gctccccctt gggagactcc agggagaagg cattgcttcc tccctgggtgt gaactcttcc 2880
 tttgttatttc catccactat cctggcaact caaggtgtct tctgttaact gaagcctgct 2940
 ccttcttgtt ctgccttcca gagatttgct caaatgtca ataagcttta aattaaactc 3000
 tacttcaaga aaaaaaaaaacc g 3021

<210> 7
 <211> 267
 <212> DNA
 <213> Homo sapiens

<400> 7
 gaacatttcca gatacctatac attactcgat gctgttatac acagcaagat ggctttgaac 60
 tcagggtcac caccagctat tggaccttac tatgaaaacc atggataccca accggaaaac 120
 ccctatccccg cacagccac tgggttcccc actgtctacg aggtgcatacc ggctcagttac 180
 taccctgtttcc ecgtgccccca gtacgccccg agggtcctga cgcaggcttc caaccccg 240
 gtctgcacgc agcccaaatac cccatcc 267

<210> 8
 <211> 3443
 <212> DNA
 <213> Homo sapiens

<400> 8
 gggcgcccg gggcgagtag ggcgcgagct a caggaggc ggaggcggag gcggaggcg 60
 agggcgcccg agcgcggcct ggagcgcggc aggtcatatt gaacatttcca gatacctatac 120
 attactcgat gctgttatac acagcaagat ggcttgcac tcagggttcac caccagctat 180
 tggaccttac tatgaaaacc atggataccca accggaaaac ccctatccccg cacagccac 240
 tgggttcccc actgtctacg aggtgcatacc ggctcagttac taccctgtttcc ecgtgccccca 300
 gtacgccccg agggtcctga cgcaggcttc caaccccg 360
 cccatccggg acagtgtgca cctcaaaagac taagaaagca ctgtgcatacc 420
 ggggacccctt ctcgtggag ctgcgtggc cgctggctt ctgtggaaatg tcatggcag 480
 caagtgtcc aactctggga tagagtgcga ctccctcaggat acctgcatacc 540
 ctgggtgtat ggctgtcatac actgccccgg cggggaggac gagaatcggt gtgttcgcct 600
 ctacggacca aacttcatcc ttcaggtgtt ctcatctcaggat aggaatgcctt 660
 gtgccaagac gacttggaaac agaactacgg gcggggcgcc tgcaggagca tgggtataa 720
 gaataattt tactctagcc aaggaatagt ggatgacagc ggatccacca gctttatgaa 780
 actgaacaca agtgcggca atgtcgatat ctataaaaaa ctgtaccacca gtgtatgcctt 840
 ttcttcaaaaa gcaatgtttt ctgttacgttgc tatagctgc ggggtcaact tgaactcaag 900
 cccggccaggac aggatcgtgg gcggcgagag cgcgcctccgg ggggcctggc cctggggcagg 960
 tcagcctgca cgtccagaac gtccacgtgt gcggaggctt catcatcacc cccgagtgg 1020
 tcgtgacagec cgcggccactgc gtggaaaaac ctcttaacaa tccatggcat tggacggcat 1080
 ttgcggggat tttagacaa tctttcatgt tctatggaccc cggataccaa gtggaaaaag 1140
 tgatttctca tccaaattat gactccaaga ccaagaacaa tgacattgcg ctgtatgaagc 1200
 tgcagaagcc tctgactttc aacgacccatg tggaaaccatg gtgtctgccc aacccaggca 1260

tcatgtgcac gccaacacag ctctgctgga tttccgggtg gggggccacc gaggagaaag 1320
 ggaagaccc agaagtgtg aacgctgcc aaggcttct cattgagaca cagagatgca 1380
 acagcagata tgcctatgac aacctgtatca caccagccat gatctgtgcc ggcttcctgc 1440
 agggaaacgt cgattcttgc cagggtgaca gtggaggcc tctggtcact tcgaagaaca 1500
 atatctggtg gctgataggg gatacaagct ggggtctgg ctgtgccaaa gcttacagac 1560
 caggagtgtc cggttattca cggactggat ttatcgacaa atgagggcag 1620
 acggctaatac cacatggtct tcgtccttga cgtcgttta caagaaaaca atggggctgg 1680
 ttttcttcc cctgtcatga ttacttta gagatgattc agaggtcaact tcattttat 1740
 taaacagtga acttgtctgg ctttggcaact ctctgccatt ctgtgcaggg tgcagtggct 1800
 cccctgcca gctgtctc cctaaccct tgcggcaag ggggtatggc cggctgggt 1860
 tgggcaactgg cggtcaagtg tggaggagag gggggaggc tgccccattt agatcttcc 1920
 gctgatgtt tttcaggggc caattttggc tgagcatggc gctgtcacct ctcagctgct 1980
 ggatgacttg agatgaaaaa ggagagacat ggaaaggagg acagccaggt ggcacctgca 2040
 gccggctgcct ctggggccac ttggtagtgt ccccaagccta cctctccaca aggggattt 2100
 gctgatgggt tcttagagcc ttagcagccc tggatggtgg ccagaaataa agggaccagc 2160
 ccttcatggg tggtacgtg gtagtcaact tgcgggggaa acagaaacat ttttggctt 2220
 atgggggttag aatataagaca gtgccttgg gtgcgggggaa agcaattgaa aaggaaactt 2280
 ccctgagcac tcctggtgca ggtctccacc tgcacattgg tgggggctcc tggggaggag 2340
 actcagccctt ccttcctcatc cttccctgacc ctgcctctag caccctggag agtgcacatg 2400
 cccctggcc ctgggcaggc ggcggcaagtc tggcaccatg ttggccttca caggcctgct 2460
 agtcaactggc aattggggc catgggggaa atcaaggatg ctcagtttaa ggtacactgt 2520
 ttccatgtta tggatcata cattgttacc tcagtgctcc tggaaactta gcttttgatg 2580
 tctccaaagta gtccacccctt atttactct ttgaaactgt atcatctttt ccaagtaaga 2640
 gtgggtggctt atttcagctg ctttgacaaa atgactggct cttgacttta cgttctataa 2700
 atgaatgtgc tgaagcaaa tggccatggt ggccggcaag aagagaaaaga tggatgggt 2760
 tttggactct ctgtggtccc ttccaaatgt gtgggttcc aaccagggggaa agggccctt 2820
 ttgcattgcc aagtgcata accatgagca ctactctacc atggttctgc ctccctggcca 2880
 agcaggctgg tttcaagaa tggaaatgaat gattctacag ctggactta accttgaat 2940
 gggaaatgtt gcaatcccattt tgcaggatc cgtctgtca catgcctctg tagagagcag 3000
 cattcccaagg gacattggaa acagttggca ctgtaaagggtt cttgtcccccc aagacacatc 3060
 ctaaaagggtt ttgtatgtt gaaaacgtt tccctttta ttggcccttc ttatgtt 3120
 gaacaactgt ttgtctttt ttgtatcttt tttaaactgt aaagttcaat tggaaaatg 3180
 aatatcatgc aaataaaattra tgcgatttttt ttttcaaaagt aaccactgca tctttgaatg 3240
 tctgcctgggtt gagtaggacc agcctccattt tcccttataag ggggtgtatgt tgaggctgct 3300
 ggtcagagga ccaaagggtga ggcaaggcca gacttgggtc tccctgtgggtt ggtgcctca 3360
 gttcctgcag cctgtccctgt tggagaggc cctcaaatga ctcccttta ttattctatt 3420
 agtctgtttc catggggcgtg ata 3443

<210> 9

<211> 254

<212> DNA

<213> Homo sapiens

<400> 9

gtgcgtgcacc agggccaccat cctggccaaag actgggacag tgccttggca ggtacggctc 60
 ctggaggccctt cccgtgcctt cgaggtgtca gagaacggca acctggtagt gagtgggaag 120
 gtgtaccatgtt gggatgaccc ttggcccttgc accccggaaag ccccaaaaaa 180
 aaccccaacgg agcccttca cctggcccaag gctgaagttt acaaggagct ggcgtctgcgt 240

ggctacgact acgg

254

<210> 10

<211> 8470

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (4131)

<220>

<221> unsure

<222> (5117)

<220>

<221> unsure

<222> (5552)

<400> 10

cggccgtcga cacggcagcg gccccggctt ccctctccgc cgcgcgttcag cctcccgctc 60
 cggccgtcga cggcgtcgctt ctcggccggcc cgcacccggc cccggcgccctt caccagagca 120
 gccatggagg aggtgggtat tgccggcatg tccgggaagc tgccagagtc ggagaacttg 180
 caggagttctt gggacaacctt catggcggtt gtggacatgg tcaacggacga tgaccgtcgc 240
 tggaaaggcg ggctctacgg cctggccggc cgggtccggca agctgaagga cctgtctagg 300
 tttgtatgcctt ccttcttcgg agtccaccccc aagcaggcac acacgtggaa ccctcagctg 360
 cggctgtgc tggaagtcac ctatgaagcc atcgtggacg gaggcatcaa cccagattca 420
 ctccgagggaa cacacactgg cgtctgggtt ggctgtgagcg gctctgagac ctcggaggcc 480
 ctgagccgag accccgagac actcgtgggc tacagcatgg tgggtgcca gcgagcgatg 540
 atggccaaacc ggctctccctt ctttttcgcac ttcagaggcc ccagcatcg actggacaca 600
 gcctgtcctt ccagcgtat ggccctgcag aacgcctacc aggcctatcca cagcggggcag 660
 tggccctggcc ccatcggtt gggcatcaat gtctgtctga agcccaacac ctccgtgcag 720
 ttcttgaggc tggggatgtt cagccccggag ggccacctgca aggccttcga cacagcgggg 780
 aatgggtactt gccgtcgga ggggtgtggg gccgtctgc tgaccaagaa gtccctggcc 840
 cggcgggtgt aegccaccat cctgaacgcg ggcaccaataa cagatggctt caaggagcaa 900
 ggcgtgaccc tccccctcagg ggatatccag gagcagtcac tccgtcggtt gtaccagtcg 960
 gccggagtgg cccctgagtc atttgaatac atcgaagccc acggcacagg caccaaggtt 1020
 ggcgacccccc aggagctgaa tggcatcacc cgagccctgtt ggcacccccc ccaggagccg 1080
 ctgtcgtatcg gtcccaacatgg gggcacccgg agccagcctc ggggtggca 1140
 gcccctggcca aggtgtgtt gtccctggag cacgggtctt gggccccccaa cctgcacttc 1200
 catagccccca accctgagat cccagcgctt ttggatgggc ggctgcaggtt ggtggaccag 1260
 cccctggcccg tccgtggcgaa caacgtgggc atcaactt ttggcttcgg gggctccaaa 1320
 cgtgcacatc atccgtggc ccaacacgcg gccggccccc gcacccggcc cacatgccac 1380
 cctggcccggtt ctgtcgccgg ccagcggacg caccctgtt ggcgtgcaga agctgtgtt 1440
 gcagggccctc cggcacagcc agggccctggc ttccctgagc atgtgaacga catcgccgtt 1500
 gtcccccggacc accggccatgc cttccctggg ctacgtgtt ctgggtgggtt agacgcgggtt 1560
 gcccagaggtt gcaacgggtt cccgtggcg agcgcccgctt ctgttgcac tggcttcgg 1620
 tgggcacaca gtcggcgccggg atggggctga gcttcgtcg cctggaccgc ttcccgagatt 1680

ccatccctacg ctccgatgag gctgtgaacc gattcggcct gaaggtgtca cagctgctgc 1740
 tgagcacaga cgagagcacc tttgatgaca tcttccatcc gtttgtgagc ctgactgcc 1800
 tccagatagg cctcatagac ctgtcgagct gcatggggct gaggccagat ggcacatcg 1860
 gccactccct gggggaggtg gcctgtggct acgcccacgg ctgcctgtcc caggaggagg 1920
 ccgtccctcgc tgccctactgg aggggacagt gcatcaaaga agcccatctc cccgcggcgc 1980
 ccatggcagc cgtgggcttg tcctgggagg agtgtaaaca gcgtgcccc cccggcggtgg 2040
 tgccccccgc cacaactcca aggacacagt caccatctcg ggacctcagg ccccggtgtt 2100
 tgagttcggt gaggcgtgaa ggaaggaggg tgggtttgcc aaggagggtgc ggaccggcgg 2160
 tatggcccttc cactcctact tcatggaggc cactgcaccc ccaactgtgc aggagctcaa 2220
 gaaggtgatc cggggagccga agccacgttc agcccgtgg cttagcacct ctatccccga 2280
 ggcccagtgg cacagcagcc tggcacgcac gtcctccgccc gaggataatg tcaacaacct 2340
 ggtgagccct gtgtgttcc aggaggccct gtggcacgtg cctgagcacg cgggtgggtct 2400
 ggagatcgcg ccccacgcgg tggcgaggg tggctgtgaag cgtggcctga agccgagctg 2460
 caccatctac cccctgtatga agaaggatca caggacaaac ctggagttct tcctggcgg 2520
 catcgccagg ctgcacccctc caggcatcga cgccaaacccc aatgccttgc tcccacctgt 2580
 ggagtccccca gctccccggag gaactccctt catctccccca ctatcaagt gggaccacag 2640
 cctggcctgg gacgcggccgg cccggagga ctccccaaac gttttaggtt cccctcagc 2700
 caccatctac acatgcacac caagctccga gtctcctgac cgctacccgtt tggaccacac 2760
 catcgacggc cgcgtccctc tccccggccac tggctacctg agcatagttt ggaagacgt 2820
 ggccccgaccc ctggggctgg gctgcagggc gctgcctgtg gtgtttgagg atgtgggtct 2880
 gcaccaggcc accatcttgc ccaagactgg gacagtgtcc ctggaggtac ggctcttgg 2940
 ggcctccctgtt gcttcgagg tggcagagaa cggcaacctg gtatgtggat ggaagggtgt 3000
 ccagtggat gacccctgacc ccaggcttcc cgtaccaccc gaaagccccca cccccaaccc 3060
 cacggagccc cttttcttgg cccaggctga agtttacaag gagctgcgtc tgcgtggcta 3120
 cgactacggc cctcatttcc agggcatcct ggaggccage ctggaaagggtg actcgccggag 3180
 gctgtgtgg aaggataatg ggtgatgtca tggacaccat gctgcagatg tccatcctgg 3240
 gtcggccaag cacggcctgtt acctgcccac ccgtgtcacc gcatccaca tcgaccctgc 3300
 caccacacgg cagaagctgtt acacactgca ggacaaggcc caagtggctg acgtgggtgt 3360
 gagcagggtgg ctgagggtca cagtgccggg aggccgtccac atctccgggc tccacactga 3420
 gtcggccccc cggccggcagc aggacgagca ggtgcccattc ctggagaagt tttgtttcac 3480
 tccccacacg gaggagggggt gcctgtctga gcacgtgtcc ctggaggagg agctgcaact 3540
 gtgcaaggggg ctggtcgagg cactcgagac caaggtgacc cagcaggggc tgaagatgg 3600
 ggtgccccggaa ctggatgggg cccagatccc cccgggaccc ctacacagcag gaaactgcccc 3660
 ggctgtgttc ggctgcctgc aggcttcagc tcaacgggaa cctgcagctg gagctggcgc 3720
 aggtgtggc ccaggagagg cccaaagctgc cagaggaccc tctgtcagc ggctcttgg 3780
 actccccggc actcaaggcc tgcctggaca ctgcccgtggaa gaacatgccc agctgaaga 3840
 tgaagggtgtt ggaggtgtgt gcccggccacg gtcacctgtt tccctgcattt ccaggctgc 3900
 tcagccccca tccccctgtc cagctgagctt acacggccac cggccggccac cccaggccc 3960
 tggagggtgc ccaggccggag ctgcagcage acgacgttgc ccaggccag tgggatcccc 4020
 cagacccctgc ccccaagcgcc ctggggcagcg cggacccctt ggtgtcaac tggctgtgg 4080
 ctggccctcgg ggacccggctt cagctctcag caacatgggt gctgcctgtt nagaagggggg 4140
 ctttctgttc ctgcacacac tggctccgggg gaccccttc gggacatcg tggcttctt 4200
 cacctccact gagcccgagt atggccaggcatcctgagc caggacgcgt gggagagct 4260
 ctteccagg gtgtcgctgc gctgggtggg cctgaagaag tccctctacg gctccacgt 4320
 cttectgtgc cggccggccca ccccgccaggaa cagccccatc ttctggccgg tggacgatac 4380
 cagcttcgc tgggtggagt ctctgaaggcatcctggctt gacgaagact tttccccggc 4440
 ctgtgtggctt gaaggccatc aactgttcca cctcggccgtt ggtgggtttt gtaactgtc 4500
 tccggcggaga gccccggcggaa acgctccgggt gttgtgtgtt ctccaaacctc agcagcacct 4560

cccacgtccc ggaggtggac ccgggctccg cagaactgca gaagggtgtt cagggagacc 4620
 tggatgaa cgtctaccgc gacggggctt gggggctt cggccacttc ctgctggagg 4680
 aggacaagcc tgaggagccg acggcacatg ccttggatg caccctcacc cggggggacc 4740
 tgcctccca tccgctgggt ctgctctcg ctgcgcctg cccagccac ctgcctggc 4800
 gcccagctct gcacggctca ctacgcctcc ctcaacttcc gcacatcat gctggccact 4860
 ggcaagctgt cccctgatgc catcccaggg aagtggacct cccaggacag cctgcttagt 4920
 atggagttct cggggccgaga cgcacggc aagcgtgtga tggactggt gcctgccaag 4980
 ggcctggcca cctctgtctt gctgtcaccc gacttctctt gggatgtgcc ttcactgg 5040
 acgctggagg aggcggccctc ggtgcctgtc gtctacagca cgcctacta cgcgtggc 5100
 gtgcgtgggc ggggcncccc cggggagacg ctgctcatcc actcgggctc gggggggcgt 5160
 ggccaggccg ccacgcctat cgcctcagt ctggctgcc gcgttccac caccgtggg 5220
 tcggctgaga agcggggcgt a cttccaggcc aggtttttttt agtcgacag caccagctt 5280
 gccaactccc gggacacatc cttcgagcag catgtgtgtt ggcacacggg cgggaaggc 5340
 gttgacccctt ttttgaactc cttggcgaa gagaagctgc aggcacggc gagggtctt 5400
 gctacgcacg gtcgtttctt ggaaattggc aaatttcgacc ttttctcagaa ccacccgtc 5460
 ggcacatgtt ttttccctgaa gaacgtgaca ttccacgggg tcttacttgg tgcgttctt 5520
 aacgagagca gtgctgactg gcgagggtt tggcgttgc tgcaggccgg catccggat 5580
 ggggtgttac ggcccttcaa gtgcacggc tttccatgggg cccaggtggc ggacgcctt 5640
 cgctacatgg cccaaaggaa gcacattggc aaagtcgtcg tgcagggtct tgcggaggag 5700
 cggaggccag tggctgaagg gggccaaacc caagctgatg tggccatctt ccaagaccc 5760
 ctggccggcc cacaagagct acatcatcc tgggtgtctt ggtggcttcg gctggagtt 5820
 ggcgcagtgg ctgatacagc gtgggggtgca gaagctcggtt ttgacttctt gctccggat 5880
 cccggacaggc taccaggcc a gcaggctccg cccgtggagg cccaggccgc tacagggtca 5940
 ggtgtccacc agcaacatca gctcaacttgg gggggccccc ggcctcattt cggaggccgc 6000
 gcaagtttgc gcccgtggc ggcgtttca acctggccgt ggttttgg gatggcttgc 6060
 tggagaacca gaccccaagag ttcttccagg acgtctgca gccaagtttac agcggcaccc 6120
 tgaaccttggc cagggtgacc cggggcgtt ccctgagctg gactactttt tggcttctt 6180
 ctctgtgacc tggggcgtt gcaatgggg acagagcaac tacggctttt ccaattttcc 6240
 ccatggagcg tattttgttgg aaacgcggc acgaaggccctt cccaggccctt gccgtgcagt 6300
 ggggccttccat cggcgacgtt ggcattttgg tggagacat gacaccaac gacacgatcg 6360
 tcagtggcac gctggccctt cgcacggcgtt cctggcttgg ggtgtggac cttttccat 6420
 accagcccca catggccctt gcaagtttgc tggctggcttga gaaggctgcg gctatagg 6480
 acaggacacg ccacgcggac ctgggtggagg cccgtggcaca catccctggc atccgcact 6540
 tggctgtgtt caacctggac agtcacttgg cggaccttgg cctggactcg ctcatgagcg 6600
 tggaggtgcg ccagacgtgt gaggctgagc tcaacccgtt gctgtccgtt cccggagggtc 6660
 ggcaacttccac gctccggaaa ctgcaggagc tggcttccaaa ggcggatgag gccagcgagc 6720
 tggcatgca ccaccccaaa ggaggatggt ctggcccttcc agcagactca gctgaaccc 6780
 cgcctcccttgc tggtaaccc gggggccccc accctgatgc ggcacacttgc cccgtgcagag 6840
 ctccggaggg cccctgttcc tggtgaccc aatttcgaggg ctccaccacc gtttccaca 6900
 gcctggccctc cccggcttccat gtcacttccat atggcccttgc gtcaccccg gctgcggccc 6960
 ttgacagcat ccaccccttgc gtcacttccat acatcgacttgc catcaggccat gtcaccc 7020
 agggcccttca cccgggtggcc ggtacttccat acggggcttgc cggccctt gaaatgtgt 7080
 cccagcttgcac gggccaggccag agcccagccca ccacccacaa cccgttccat ctgttcgac 7140
 gtcggccacat ctacgtacttgc gtcacttccat agcgttccat ggcacacttgc accccaggct 7200
 gtgaggcttgc ggttgacacg gaggccat tgcacttccat gtcacccat gtcaccc 7260
 agcacaacag ggtgtggag ggcgtgttgc cccgttgaccc ggtgtggcag 7320
 cccggccgttgc cccgttccat aagagccacc agggcccttgc cccggccaggag ctgagctttt 7380
 cggccggcgttgc ttttccat aagctgttgc cccgttgacca gtcaccc 7440

accatggcaa cgtatgcta ctgcgcgcca agacgggtgg cgcctacggc gaggacctgg 7500
 gcgccgacta caacctctcc caggtatgcg acggaaagt atccgtccac gtcatcgagg 7560
 gtgaccaccc cacgctgtg gagggcageg gcctggagtc catcatcagc atcatccaca 7620
 gctccctggc tgagccacgc gtgagcgtgc gggagggcta gcccgtgcc cccgcgtcc 7680
 accggaggcc acctccacccat ccccaaaaaa tccccccca ccccccggcat gcaacggat 7740
 tgaagggtcc tgccgggtggg accctgtccg gcccagtgcc actggggggg gaggttagct 7800
 agacgttaggt gttaggcgtg tccccccac cccgcgcctc ccacggcacc tcggggacac 7860
 cagagctgcc gacttggaga ctccctggct gtgaagagcc ggtgggtgccc gtgcccgcag 7920
 gaactggggc tgggcctcggt gcgcggcgtgg ggtctgcgt tggctttct gtgcttgat 7980
 ttgcataattt attgcattgc tggtagagac ccccaaggcc gtccacccctg ccaagactcc 8040
 tcaggcageg tgggggtccc gcactctgc cccattttcc cgtatgtcccc tgccggcg 8100
 ggcagccacc caagcctgtt ggctgcgcgc ccccttcggc caggcattgg ctcagccgc 8160
 tgagtggggg gtcgtggggcc agtccccgag gactggggccc ctgcacaggc acacagggcc 8220
 cggccacacc cagcggccccc cccgcacagcc acccggtgggg tggccgcctt atgcccggcg 8280
 cccggccacca actccatgtt tgggtttgt ctgtgtttgt tttcaagaa atgattcaaa 8340
 ttgtcttgat gattttggaa ttactgtaa ctgtcagtgt acacgtctgg accccgtttc 8400
 atttttacac caatttggta aaaaatgtgc tctcagcctc ccacaattaa accgcatgtg 8460
 atctccaaaa 8470

<210> 11
 <211> 812
 <212> DNA
 <213> Homo sapiens

<400> 11
 gccgcagcca atcagcgcgc gtgccccggc cccctgcgtct cttgcgtcaa gacggccgtg 60
 ctgagcgaat gcaggcgact tgcgagctgg gagcgattta aaacgccttg gattccccc 120
 gcctgggtgg ggagagcggag ctgggtgccc cctagattcc cccgcgcgc acctcatgag 180
 cccgaccctcg gctccatgga gccccggcaat tatgcacact tggatggagc caaggatatac 240
 gaaggcgttgc tggagcggg agggggggcgg aatctggtcg cccactcccc tctgaccaggc 300
 caccgcgg cgcctacgt gatgcctgtt gtcaactatg ccccttggta tctgccaggc 360
 tggcgggagc gccaaagcaa tgccacccat gcccctgggt gccccagggg acgtccccag 420
 ctcggcgcc ttatggttac tttggaggcg ggtactactc ctgcccgtgt tcccgagct 480
 cgctgaaacc ctgtgcccag gcagccaccc tggccgcgtt ccccgccggag actcccacgg 540
 cccggggaaaga gtaccccaagc cggccactg agtttgcctt ctatccggaa tatccggaa 600
 cctaccagcc tatggccagt tacctggacg tggctgtggt gcagactctg ggtgctccctg 660
 gagaaccgcg acatgactcc ctgttgcctg tggacagtta ccagtcttgg gctctcgctg 720
 gtggctggaa cagccagatg tggccagg gagaacagaa cccaccagggt cccctttggta 780
 aggccaggatt tgccagactcc agcggggcagc ac 812

<210> 12
 <211> 2385
 <212> DNA
 <213> Homo sapiens

<400> 12
 ataagctggg gtaaaagtatt ttgcagttt ctgcctttag gattttatta gtttctctcc 60
 cccaggccgc agccaatcag cggcggtgcc cggcccccctg cgtctttgc gtcaagacgg 120

ccgtgctgag cgaatgcagg cgacttgcga gctgggagcg attaaaaacg ctttggattc 180
 ccccgccctg ggtggggaga gcgagctgg tgccccctag attcccccgc cccgcacctc 240
 atgagccgac cctcggtctcc atggagcccc gcaattatgc caccttggat ggagccaagg 300
 atatcgaagg cttgctggga gcgggagggg ggcgaaatct ggtcgccac tccccctctga 360
 ccagccaccc agcggcgcct acgctgatgc ctgtgtcaa ctatgcccc ttggatctgc 420
 caggctcgcc ggagccgcca aagcaatgcc acccatgccc tggggtrgccc caggggacgt 480
 ccccaagctcc cggtgccttat ggtaactttg gaggcgggta ctactcctgc cgagtgtccc 540
 ggagctcgct gaaaccctgt gcccaggcag ccaccctggc cggtaccccc gcggagactc 600
 ccacggccgg ggaagagttac cccagccccc ccactgagtt tgcccttctat cggggatatac 660
 cgggaaccta ccagcctatg gccagttacc tggacgtgtc tgggtgcag actctgggtg 720
 ctccctggaga acccgacat gactccctgt tgccctgtgg aagttaccag tcttgggtc 780
 tcgctgggttgg ctggaacagc cagatgtttt gccaggaga acagaaccca ccaggtccct 840
 tttggaaaggc agcatttgca gactccagcg ggcagcaccc tcctgacgccc tgcccttttc 900
 gtcgccccgg caagaaacgc attccgtaca gcaagggca gttgcgggag ctggagcggg 960
 agtatcgccg taacaagttc atcacaagg acaagaggcg caagatctcg gcagccacca 1020
 gcctctcgga gcgccagatt accatctgg ttcagaaccc cccgggtcaaa gagaagaagg 1080
 ttctcgccaa ggtgaagaac agcgctaccc cttaagagat ctcccttgccct ggggtgggagg 1140
 agcgaaagtg ggggtgtccct ggggagacca ggaacctgca aagcccaggc tggggccaag 1200
 gactctgtg agagggccct agagacaaca ccctttccag gccactggct gctggactgt 1260
 tcctcaggag cggcctgggt acccagtatg tgcaaggaga cggaaacccca tggacagcc 1320
 cactccacca gggttcccaa agaacctggc ccagtcataa tcattcatcc tgacagtggc 1380
 aataatcactg ataaccatgta ctatcgccca tgatcggttag cctcatatatt tctatctaga 1440
 gctctgtaga gcaattttaga aaccgcttcc atgaattttag gtaattatgata ataaatttgg 1500
 aaggcgatcc ctttgcaggg aagctttctc tcagacccccc ttccattaca cctctcaccc 1560
 tggtaacacg aggaagactg aggagagggg aacgggcaga ttcgttggat ggtgtgtatg 1620
 tccgtttagc atttttctca gctgacagct gggtaggtgg acaattttagt aggctgtctc 1680
 ttccctccctc cttgtccacc ccatagggtg taccactgg tcttggaaac acccatcctt 1740
 aatacgatga ttttctgtc gtgtaaaaat gaagccagca ggtgtccccct agtcaagtcc 1800
 tccttccaga gaaaaagaga tttgagaaag tgcctgggtt attcaccatt aatttccctcc 1860
 cccaaactct ctgagtcttc ccttaatatt tctgggggtt ctgaccaaaag caggtcatgg 1920
 tttgttggac atttgggatc ccagtgaagt agatgtttgtt agccttgcatt acttagccct 1980
 tcccaggcac aaacggagtg gcagagtggt gccaaccctg tttccccagt ccacgttagac 2040
 agattcacgt gcgaaattct ggaagctggc gacagacggg ctctttgcag agccgggact 2100
 ctgagagggc catgagggcc tctgcctctg tgttcattct ctgatgtctt gtacctggc 2160
 tcagtggcccg gtgggactca tctccctggcc ggcagcaaa gccaggggt tgggtgtgtt 2220
 ccttcctgca ccttaggctg ggggtggggg gcttgcgggc gcattctcca cgattgagcg 2280
 cacaggccctg aagtctggac aaccgcaga accgaagctc cgagcagcgg gtcgggtggc 2340
 agtagtgggg tccgtggcga gcagttgggtt gttggccggc gccc 2385

<210> 13

<211> 221

<212> DNA

<213> Homo sapiens

<400> 13

dsdnrstatac tttctgtgtg gtgcagccctt gttggcagtg ggcattctggg tggtaatcga 60
 tggggcatcc tttctgaaga tcttcgggccc actgtcgatcc agtgcctatgc agtttgcataa 120
 cgtggggctac ttccatcg cagccggcgt tgggtttt gcttgggtt ccctgggtc 180

ctatggtgct aagactgaga gcaagtgtqc cctcgtqacq t

221

<210> 14

<211> 1533

<212> DNA

<213> *Homo sapiens*

<400> 14

gggcacgcac acattctggg aagccacttg ccccacccct gggctgcttc ttcttgagat 60
caggaggggc gttgcccagg gctggtgttgc ccagggtaggag gcctgctgag gcagtggttgc 120
tggggatcggttccaggca gcagggggca gcagggtcaa ggagaggcta actggccacg 180
ggtggggcca gcaggcgccc agaaggaggtttaaagcgc ctaccctgccc tgcagggtgag 240
cagtggtgtg tgagagccag gccgtccctc tgccctgccc ctcagtgccaa acacccggg 300
gctgtttgtt cctttgtggc gcctcagcag ttcctgttt tcagaactca ctgccaagag 360
ccctgaacag gagccaccat ggcagtgctt cagttcatt aagaccatga tgatcctctt 420
caatttgctc atcttctgt gtggtgccgc cctgttggca gtggcatct gggtgtcaat 480
cgatggggca tccttctga agatcttcgg gccactgtcg tccagtgccca tgcaagtttgt 540
caacgtgggc tacttctca tcgcagccgg cgttgtggc tttgtctttt gtttccctggg 600
ctgctatggc gctaagactg agagcaagtg tgccctcgacgttcttccatccct 660
cctcatcttc attgctgagg ttgcagctgc tgggtgcgc ttgggttaca ccacaatggc 720
tgagacttc ctgacgttgc tggtagtgcc tgccatcaag aaagattatg gttcccgagg 780
agacttcaact caagtggtgg aacaccat gaaagggtc aagtgtgtg gtttccaccaa 840
ctatacgat tttgaggact caccctactt caaagagaac agtgccttcccccattctg 900
ttgcaatgac aacgtcacca acacagccaa tggaaacctgc accaagcaaa aggtcacga 960
ccaaaaagta gagggttgc tcaatcagct ttgtatgac atccgaacta atgcagtcac 1020
cgtgggtgtt gtggcagctg gaattggggg ctcgcagctg gtcgcattga ttgtgtccat 1080
gtatctgtac tgcaatctac aataagtccat tttctgcctc tgccactact gtcgcacat 1140
gggaactgtg aagaggcacc ctggcaagca gcagtgattt ggggaggggc caggatctaa 1200
caatgtcaact tggggcagaa tgacactgccc tttctgtc cagacttggg gctagatagg 1260
gaccactctt ttttaggcgt gcctgacttt ctttccattt gttgggtggat ggggtgggggg 1320
cattccagag cctctaaggt agccagttt gttgccttcc ccccccagtct attaaaaccct 1380
tgatatgccc cttaggccta gtgggtatcc cagtgctca ctggggatg agagaaaggc 1440
attttatagc ctgggcataa gtgaaatcag cagagccctt ggggtggatgt gttagaaggca 1500
cttcaaaatg cataaaccctg ttacaatgtt gcc . 1533

1533

<210> 15

<211> 472

<212> DNA

<213> *Homo sapiens*

<400> 15

tcagagaaaa ctcaaacttt attgagagaa ttttcaaatt ttcagtcaca ttttcaatgt 60
gacatcagcc atgtgtgtag cttcagcttgc tttttttttt aacttatggc tgcccatctc 120.
ctgtttttt agtcttagca tgcttaggat taggtggagt cttctttttt acatcagagc 180
catctccacg ctcaactccga gtctttcca gatccatTC ctggcaatca ctttttactt 240
tacgtttttc gatcgagggt gtcccttctc tctttgtcc aggttcaata ttctgattgt 300
cagttgggtgg ttcccttgc tgagattcac cgggagccac gaatgcaacc acatcgggag 360
ccttctgacc atctctttt cctctggatc ttgatctcac tcgtgcactc atcgctgcaa 420

ctagaagatc gtgaactgaa gaacttgagt cagcagagag cctggcgaag aa 472
 <210> 16
 <211> 478
 <212> DNA
 <213> Homo sapiens

<400> 16
 ctteattctt cgccaggctc tctgctgact caagttcttc agttcacat cttctagttg 60
 cagcgatgag tgacacgagtg agatcaagat ccagaggaag aggagatggg caggaggctc 120
 cccatgtggt tgcatcgtg gctcccggtg aatctcagca agaggaacca ccaactgaca 180
 atcaggatata tgaacctgga caagagagag aaggaacacc tccgatcgaa gaacgtaaag 240
 tagaagggtga ttgccaggaa atggatctgg aaaagactcg gagtgagcgt ggagatggct 300
 ctgatgtaaa agagaagact ccacctaata ctaagcatgc taagactaaa gaagcaggag 360
 atggcagcc ataagttaaa aagaagacaa gctgaagcta cacacatggc tgatgtcaca 420
 ttgaaaatgt gactgaaaat ttgaaaattc tctcaataaa gtttagttt tctctgaa 478

<210> 17
 <211> 198
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (191)

<400> 17
 cccgctgtac caccccgca tttctgcgc cggcgaggaa caagaccaga aggactcctg 60
 caacgggtgac tctggggggc ccctgatctg caacgggtac ttgcaggggcc ttgtgtctt 120
 cggaaaagcc ccgtgtggcc aagttggcgt gccaggtgtc tacaccaacc tctgcaaatt 180
 cactgagtgg nattaagg 198

<210> 18
 <211> 465
 <212> DNA
 <213> Homo sapiens

<400> 18
 tggatgttggaa gtatgttattt attttacaaa aataaatcac catcttcgga ccattttgttag 60
 actggaaat ttcgagcaat gagtgccca cacggacgag tgccctgggtg actccctgtat 120
 gttcgctgtca ccccccaggc caccttggcg cccgcattgat cctcgcttcc cactcccgcc 180
 ctccaaactcc ctccctcgc agccgcattt caccttctgc tgtttatttg tctgcagagc 240
 gcctggacac cggaaaaggc gattccctga ggcctggag ttggagacaa ttccctgggtc 300
 agaattttaaa catctttcta aggttaagcgc tgctccaaaa ctttcgcggc cgtggggact 360
 ttgcaccagg ggcgggttggg aaggaagttt ggcctccacg ggttcctggg caaccgcggc 420
 ctgttggaaa aaggttctgg gtcaaataat ttaacttcgg aggag 465

<210> 19

<211> 204

<212> DNA

<213> Homo sapiens

<400> 19

ggcgaaaaaca ggccggcgctg gacctgtacc cctacgacgc cgggacggac agcggcttca 60
ccttccttc ccccaacttc gccaccatcc cgccaggacac ggtgaccgag ataacgtcct 120
ccttccttcag ccacccggcc aactccttct actacccgcg gctgaaggcc ctgcctccca 180
tcggccagggt gacactggtg cggc 204

<210> 20

<211> 294

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (287)

<400> 20

gagatttctc ttcaatggct tcctgtgagc tagagttga aaatatctta aaatctttag 60
cttagagatgg aagttagcttgc gacgattttc attatcatgt aaatcgggtc actcaaggggg 120
ccaaaccacag ctgggagcca ctgctcaggg gaaggttcat atggactttt ctactgcctca 180
aggttctata caggatataa aggtgcctca cagtagatag ctggtagcaa agtaagaaga 240
aacaacact gatctcttgc tgccacccct ctgacccttt ggaactnctc tgac 294

<210> 21

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 21

atcagaacaa agaggctgtg tc

22

<210> 22

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 22

atctctaaag ccccaacctt c

21

<210> 23
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 23
tgccgaagag gttcagtgc

19

<210> 24
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 24
gccacacgtgg tactgtccag at

22

<210> 25
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 25
gctgcaagtt ctccacattg a

21

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Synthetic

<400> 26
cagccgcagg tgaaacac

18

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 27

tggcttgaa ctcagggtca

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 28

cggatgcacc tcgttagacag

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 29

cggcaacctg gtagtgagtg

20

<210> 30

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 30

cgcägctcct tgtaaaacttc äg

22

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Synthetic

<400> 31
cgggAACCTA CCAGCCTATG 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 32
caggCAACAG GGAGTCATGT 20

<210> 33
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 33
tgggcatctg GGTGTCAA 18

<210> 34
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 34
cggtgcgtat GAGGAAGTA 19

<210> 35
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 35
gccccatctcc TGCTTCTTCA GT 22

<210> 36

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 36

cgtggagatg gctctgatgt a

21

21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/24331

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, Biosis, Embase, Cancerlit, Scisearch, WPIDS, USPATFULL
search terms: CSG, cancer specific gene, cancer, diagnosis

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database SCISEARCH, Accession Number 307617, OLSSON et al. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urologic Clinics of North America. May 1997, Vol. 24 No. 2, pages 367-&.	1-6
Y	CHO-CHUNG et al. Antisense Oligonucleotides for the treatment of cancer. Current Opinion in Therapeutic Patents. 1993, Vol. 3, No. 12, pages 1737-1750, see entire document.	1-6
A,E	BUSSEMAKERS et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research. 01 December 1999, Vol. 59, No. 23, pages 5975-5979.	1-7

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	
"B"	earlier document published on or after the international filing date	"X"
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"&"

Date of the actual completion of the international search	Date of mailing of the international search report
10 FEBRUARY 2000	07 MAR 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer GEETHA P. BANSAL Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/24331

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (?):

A61K 39/395, 48/00; C12P 19/34; C12Q 1/68; G01N 33/53, 33/574, 33/546, 33/567

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/130.1, 141.1, 155.1, 183.1; 435/6, 7.1, 7.23, 7.9, 91.2; 436/501, 504, 505, 547; 514/44; 536/23.5